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Introduction 
Powders are not only intermediate products, but they have a significant impact on drug 
performance or are used directly as dosage forms. Particle size and size distribution are very 
important characteristics of powders having significant effects on flowability [1], dissolution 
properties [2], release kinetics [3] etc. Therefore, particle engineering is a very important step 
in the processing of pharmaceutical solids. For many applications particles with special 
requirements, like sizes in the lower micrometer range, are needed. The positive effects of 
micronization on the solubility of poorly soluble drugs [4], the homogeneous distribution 
within long term release matrices [5] or effective pulmonary application [6] are just some 
examples. Several methods for the processing of pharmaceutical powders are available and 
very well validated. However, only few detailed studies exist for micronization of proteins. 
Proteins belong to a group of drugs so-called biopharmaceuticals (recombinant proteins, 
monoclonal antibodies and nucleic acid-based drugs) [7], which were established on the 
market during the last decades. Starting with the approval of the first recombinant insulin in 
the early 1980s, biopharmaceuticals have more and more been used as highly potent drugs. 
Facilitated by advances in molecular biology and immunology and description of diseases at 
the molecular level rational drug design was enabled [8]. And due to the improvement of 
biotechnical methods to modify DNA there are now virtually unlimited options to create 
recombinant proteins for every demand. Especially in the fields of cancer, diabetes, growth 
disturbances, hemophilia and hepatitis [7], new therapeutic options were made possible by the 
development of biopharmaceutical drugs. The immense variability in structure and the 
possibility to evoke very specific effects in the body are the most salient characteristics of 
biopharmaceuticals. 
But as always, there are two sides of the coin: stability problems of the amino acids backbone 
especially in presence of water are well known. Proteins are prone to many different types of 
chemical degradation e.g. deamidation, hydrolysis, β-elimination, oxidation or disulfide 
exchange [9]. Additionally, physical changes in the secondary or tertiary structure e.g. by 
unfolding are fatal for the bioactivity of proteins [10]. Another drawback is the fact that the 
Holy Grail, the oral administration of these drugs, has still not been found. The challenges are 
e.g. digestive enzymes, intestinal flora, acetic gastric environment and the hindered absorption 
[11], which block this preferred way of application. Therefore, as long as no satisfying 
solutions are available, innovative new ways of application have to be found for these 
challenging molecules. Creating alternatives to the parenteral delivery with its unpleasant 
 Introduction and Goals of the Thesis Chapter 1 
9 
injections and short administration intervals was the focus in drug delivery research during the 
last years. Several new ways of application were developed, like nasal [12], pulmonary [13], 
buccal [14], ocular [15], rectal [16], implantable long term release systems [3], needle free 
powder injections [17] and transdermal delivery [18]. For most of these applications proteins 
are not only processed in solid state but also delivered as a solid. This concept is based on the 
dramatically increased stability of proteins in solid state compared to solutions [19]. From the 
beginning of protein galenics most protein drugs were stored as freeze dried solids being 
disssolved before parenteral application. So longer shelf lives were obtained. However, for the 
new administration strategies not only the stability of the solid drugs but also the properties of 
the solid itself played an important role. Now being delivered in solid form protein drugs had 
to fulfill the same requirements as any other pharmaceutical powder e.g. flowability, particle 
size and size distribution of the protein particles. Especially pulmonary delivery or 
incorporation into long term release systems has special demands on these powder 
characteristics. A particle is no longer seen as a passive carrier, but rather as an essential part 
of the drug delivery system [20]. Hence processes have to be found, which allow the 
production of micron sized protein particles. Ideally existing micronization methods can be 
used from the powder processing of small molecular drugs, but maintaining their bioactivity 
during these sometimes harsh processes is a challenging task. 
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Obtaining micron sized protein particles– an overview 
There are generally two different methods to obtain protein particles in the lower micrometer 
range starting with a protein solution. For one the solidification and particle forming of the 
proteins take place in one step. Spray drying, spray freeze drying and precipitation (incl. 
supercritical fluid methods) are typical examples. The second option almost always starts with 
freeze drying of the protein solution. Afterwards the dry cake is micronized by different size 
reduction processes like jet milling, pearl milling or high pressure homogenization. These 
different methods of obtaining small protein particles will now be discussed in more detail. 
 
One step processes 
Spray drying 
Spray drying is the most often used and best investigated process of forming protein particles 
in the lower micrometer range. A liquid feed is atomized into a hot gas. The resulting fine 
droplets generate a large amount of air-water interfacial area, so that the water evaporates 
very rapidly. The whole drying process takes tens of seconds to a few seconds [21]. Due to 
the evaporation of the solvent a critical increase in temperature is prevented and the 
temperature of the formed particles remains significantly lower than the temperature of the 
drying gas [22]. However, for spray drying of proteins a lower inlet air temperature is used in 
practice to reduce the potential thermal stress [23]. Afterwards the particles are removed from 
the gas stream by cyclone separators. This separation step was improved during the last years 
so that the yield could be increased from 20 – 50 % [24] to more than 70 % by the 
development of high-performance cyclones. The quality of the product is significantly 
influenced by the chosen process parameters. And apart from the classical trial and error 
attempts experimental statistical design techniques were applied to optimize the process [25]. 
Especially lack of control over particle size and size distribution are challenges [26,27]. 
The resulting particle morphology after spray drying is not necessarily spherical. After drying 
the particles may have convoluted surfaces, asperities, holes and voids [21]. For most of the 
mentioned spray drying experiments particle sizes below 10 µm were obtained. The median 
diameters were in a size range from 2 to 6 µm. Therefore, spray drying is often used for the 
production of particles for pulmonary delivery [28]. 
Thermal stressing is more or less avoided due to the evaporative cooling, but high shear rates 
originating from the atomization process may denature proteins. For example, human growth 
hormone (hGH) was denaturated at the air-liquid interface whereas for tissue-type 
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plasminogen activator (t-PA) no negative effects were detectable [29]. Pure lysozyme lost 
about 10 % and catalase lost nearly 50 % of their initial bioactivity [30]. To overcome these 
problems different excipients for stabilization of proteins during and after the spray drying 
process were tested. By adding sucrose, trehalose, polyvinyl alcohol and mixtures thereof 
lysozyme and catalase retained almost full activity. Lactose showed good stabilization of a 
recombinant humanized anti-IgE monoclonal antibody [31] and combinations of lactose with 
dipamitoylphosphatidylcholine prevented the dimerization of hGH by spray drying [32]. 
Surfactants were recognized as useful tools to prevent the accumulation of proteins at the air-
liquid interface of the atomized droplets. Due to their amphiphilic character proteins normally 
tend to concentrate on the surface of these droplets and are then prone to aggregation and 
unfolding. Added surfactants displace the proteins and promote their stability [33]. 
While spray drying is the best established method for preparation of micron sized protein 
particles, a disadvantage may be the high amounts of excipients that are necessary to stabilize 
the proteins during the process. 
 
Spray freeze drying (SFD) 
The principle of SFD was first introduced in 1990 [34]. Similar to spray drying a solution is 
atomized, but instead of rapid drying by hot air the droplets are sprayed into a vessel 
containing a cryogenic liquid, such as liquid nitrogen. While traveling through the cryogenic 
gas the droplets begin to freeze [35] and are completely frozen after entering the liquid 
cryogen. After freeze drying micron size particles were obtained [36]. 
Due to the absence of hot air drying no solvent evaporation takes place and the resulting 
porous particles keep their spherical shape [17]. An advantage is the high product yield. At 
identical spraying conditions SFD resulted in larger (8 – 10 µm) but more porous particles 
with a larger specific surface area than at spray drying (3 µm) [37]. Nevertheless, particle size 
and morphology can be strongly influenced by varying the process parameters [38]. 
Similar to spray drying problems with protein aggregation and denaturation can occur. Ziegler 
et al. [17] determined a constant loss of 30 % bioactivity of catalase due to the SFD process. 
By systematically studying the effect of the separate steps of the process (spraying, freezing, 
drying) the large gas-liquid interface in the spraying step was identified as the primary cause 
of protein aggregation of recombinant human interferon-γ [39] and lysozyme [40]. During the 
freezing step concentrations of protein and other solutes like electrolytes increase markedly in 
the remaining unfrozen solution, which further contributes to protein aggregation and 
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denaturation [41]. Therefore, modifications were developed to minimize the time of exposure 
to the air liquid interface during the atomization step and increasing the freezing velocity. 
It was not the new concept to spray the protein solution on top of the cryogenic liquid but 
directly in the cryogenic liquid by using an insulated nozzle. It was first developed for 
enhancing the dissolution of poorly soluble drugs [42]. The ultra rapid freezing of the formed 
droplets prevents phase separation and also prevents crystal growth in frozen water. By spray 
freezing into liquid (SFL) an amorphous glass is formed before any relaxation events take 
place in the concentrated solution [41].  
The particle morphology was quite similar to SFD particles. Very porous particles with large 
specific surface areas were optained. Yu et al. produced particles of insulin and BSA with a 
median diameter of 5 µm. By sonication in methylene chloride BSA particles were further 
micronized to about 0.4 µm [40,43]. 
Comparing results from SFD and SFL showed a significant increase in protein activity and 
stability for protein particles produced by SFL. The monomer loss of BSA was reduced from 
about 5 % for SFD to 0.5 % for SFL [44], for the enzyme lysozyme 97 % activity for SFL 
made particles and 86 % for SFD made ones were obtained [40]. For insulin which tends to 
deamidation and aggregation no differences in stability compared to the bulk substance were 
determined [43]. Even for fragile lactate dehydrogenase (LDH) 98 % bioactivity were 
measured after SFL, which was similar to the freeze dried control and significantly higher 
than after SFD where about 80 % activity were determined [45]. This effect was attributed to 
the very short exposure time to the gas-liquid interface which was 2 orders of magnitude 
faster than for SFD. 
SFD and SFL are a further development of spray drying and the higher expense seems to be 
justified by the good results. 
 
Precipitation of protein crystals 
Precipitation was one of the first methods to purify proteins or to obtain protein crystals for 
structural analysis. Generally, proteins are precipitated by the reduction of solubility due to 
the addition of specific compounds or the change in process conditions. Salting-out, 
precipitation by polyelectrolytes and nonionic polymers, isoelectric precipitation and addition 
of organic solvents are common methods. Detailed information about crystallization 
conditions and crystal data for several thousand proteins can be found in the Biological 
Macromolecular Crystallization Database (BMCD) [46]. However, these data originated 
mainly from approaches to generate X-ray quality crystals for structural analysis, but for the 
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use in pharmaceutical formulations the aims are quite different. Narrow size distribution, high 
yield and quick processing are challenges for the use of precipitation in pharmaceutical 
processes [47]. 
There are different hints that proteins in crystallized form are more stable than in their 
amorphous form [48,49]. The crystalline form is thermodynamically more stable, which is the 
reason for the lower stability and higher reactivity of amorphous substances [50]. 
Additionally, it is possible to influence the release behavior by modifying crystal properties 
due to different excipients or by utilizing possible crystal polymorphisms [51]. In spite of 
these advantages with exception of insulin nearly no protein is used in crystallized form in 
pharmaceutics. Reasons for this are 1. the hard to be controlled crystallization process which 
often results in broad size distributions and 2. that not all proteins cannot easily be 
crystallized. 
Lee et al. produced uniform spherical microcrystals of α-lactalbumin of 1-2 µm by using a 
pH-shift method in presence of PEG as a stabilizer [52]. Three monoclonal antibodies 
(rutiximab, trastuzumab and infliximab) were successfully crystallized by Yang et al. [53]. As 
precipitation agents different amounts and types of PEG and salts were utilized. Depending on 
the conditions needles, rice-shaped crystals or star clusters formed in a quite homogenous 
way. The obtained size range was between 10 to 60 µm. All antibodies retained their full 
stability and activity. Reichert et al. patented a method to produce crystalline interferon alpha 
for pulmonary delivery [54]. The protein was dissolved in zinc acetate/sodium acetate 
containing medium at 4°C. Crystallization was achieved by using a temperature induction 
method. It was increased over 6 hours up to 22°C and maintained there for 5 days. The 
resulting crystal sizes ranged from 100 to less than 1 µm. After further processing it was 
possible to isolate a fraction with an average diameter of 1.8 µm. The bioactivity of interferon 
was not distinguishable from the unprocessed control. 
These are some promising results but as mentioned before the practical use in drug 
formulation has not yet been established. 
 
Supercritical fluid technology 
Supercritical fluids (SCFs) are gases or liquids at temperatures and pressures above their 
critical points (critical temperature Tc, critical pressure Pc). The 3-phase diagram indicates that 
the higher the temperature of a gas is the higher the pressure has to be to liquefy it (fig 1.1). 
At high pressures the density of the gaseous phase increased so much that it is impossible to 
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distinguish between gas and liquid. Tc is now the highest temperature at which gaseous and 
liquid phase are separated and Pc is the highest pressure where this is possible [23].  
 
 
Fig. 1.1 Carbon dioxide pressure-temperature phase diagram 
 
In practice the term supercritical fluids is assigned to substances in a pressure and temperature 
range of Tr = 1.01 to 1.10 and Pr = 1.01 to 1.5 (Tr = T/Tc and Pr = P/Pc) [55]. SCFs are 
characterized by special thermophysical properties. Liquid-like densities combined with very 
large compressibility and higher thermal diffusivities and viscosities than liquids make them 
an interesting tool. They are utilized for extraction of plant ingredients [56,57], supercritical 
fluid chromatography [58], particle production for pulmonary delivery [59], as solvents for 
enzymatic reactions [60] and several other applications. Carbon dioxide (CO2) is the most 
widely used substance, because of its low costs and nontoxic properties and its easily 
accessible critical point (304.1 K and 72.8 bar) [61]. 
Several methods were developed to use these super critical fluids for preparation of protein 
microparticles. SCFs may be used as solvents or antisolvents for the proteins to be 
precipitated. For the first variant the increased dissolving power of the SCFs is utilized to 
dissolve the proteins. Afterwards the solution is fed via an orifice into a vessel where by rapid 
expansion the protein is precipitated because of the decreasing dissolving power. This method 
is limited by the fact that only some proteins are soluble in SFCs. The second and most often 
used option is similar to the use of anti-solvent in solvent-based crystallization processes [62]. 
Proteins are dissolved in good solvents like dimethylsulfoxide (DMSO) or ethanol water 
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mixtures. The high solubility of supercritical CO2 in these solvents leads to volume expansion 
when the fluids get into contact. Due to this the solvent density is reduced and the solvation 
capacity drops which leads to nucleation and particle precipitation [22]. 
Different proteins were tested at different process conditions. Cyclosporine particles of 
150 nm were obtained by rapid expansion, but the particles were highly aggregated [63]. 
Insulin and catalase were micronized down to 3 µm respectively smaller 1 µm by using CO2 
as an antisolvent [64].  
Muhrer and Mazotti investigated the effect of different parameters on the size of lysozyme 
particles precipitated from a DMSO solution. The resulting amorphous particles had a size of 
about 250 nm, but were aggregated to particles of 20-30 µm with no big influence of any 
process parameter. After the process 75 % biological activity relative to the standard material 
was retained [65]. Thiering et al. described the relation between process temperature and 
lysozyme bioactivity, which was decreased to 60 % by increasing the temperature from 25 to 
45°C [66]. Insulin precipitated from DMSO formed particles with 90 % smaller than 4 µm. 
The FT-IR spectra showed an increase of β-sheet content with concomitant decrease in α-
helix contents. However, after dissolving the particles in 0.01 M HCl the spectra were nearly 
identical to the commercial powder [67]. Bioactivity tests in rats showed no difference to the 
unprocessed insulin [68]. 
Bustami et al. sprayed an aqueous solution of lysozyme and rhDNase into pressurized CO2 
with a mole fraction of 0.2 ethanol added. Lysozyme retained all bioactivity, but rhDNase was 
totally denatured. No monomers of rhDNase could be detected after processing at 45°C. Even 
after lowering the temperature to 20°C two-thirds were denatured, which was related to the 
acetic environment in this process [69]. 
This relatively new technique seems to be quite promising, but the process is complex and 
applicable to a few proteins only. 
 
Two step processes 
Lyophilization 
Lyophilization or freeze-drying is the most common and best investigated method to obtain 
solid proteins. However, the resulting solids have to be further processed to get 
homogeneously distributed particles in the micrometer range and freeze drying is just the first 
of the two preparation steps. The process of freeze-drying is very well investigated and often 
reviewed in literature [19,70–75]. Therefore, this process will not be discussed in detail here, 
as it would exceed the scope of this thesis. The critical steps during the three process stages 
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(freezing, primary drying and secondary drying), e.g. by freezing and drying stresses like 
solute concentration, formation of ice crystals, pH changes and effect of different excipients, 
are well known and often reviewed but still not totally understood [19,76]. Wang stated, that 
in order to get the optimal result for each protein it takes an enormous amount of time and 
labor, because there is no single, short and mature pathway to follow in formulating such a 
product [19]. This might be true for all protein processing methods. 
Anyhow, even by taking the potential risks into account, lyophilization is a very useful and 
well analyzed method to obtain stable solid proteins and most commercially available proteins 
are freeze-dried powders. 
 
Co-lyopilization of proteins with poly(ethylene glycol) (PEG) 
Morita et al. developed a method to conceive spherical protein microparticles after 
lyophilization in presence of PEG 6000 [77]. PEG was chosen because of its solubility in 
different media, which allows the co-lyophilization with proteins in an aqueous media and the 
complete removal with an organic solvent afterwards. Secondly, PEG served as a phase 
separation inducer. Protein and PEG have to be mixed in a protein specific ratio and then 
solved in water to form a clear solution. During the freezing process protein and PEG are 
separated in a continuous PEG-phase and a disperse protein-phase. Afterwards the PEG phase 
is removed by methylene chloride and the protein microparticles remain. 
The resulting spherical particles had a narrow size distribution with an average particle size of 
3-4 µm and high purity for BSA, superoxide dismutase and horseradish peroxidase. The 
activity of superoxide dismutase and horseradish peroxidase was completely maintained after 
the process. Castellanos et al. investigated the activity of γ-chymotrypsin after encapsulation 
of the protein particles in PLGA microsperes and 92 % of the initial activity was measured 
[78]. Koennings et al. described the incorporation of interleukin-18 particles produced by co-
lyphilization into lipidic matrices without any loss in bioactivity [79]. The method was also 
adapted for the preparation of dextran microspheres. Depending on molecular weight of PEG 
and dextran particles in the range of 200 nm to 10 µm were obtained [80]. 
This method seems to be very useful for the processing of very small amounts of proteins. 
 
Milling 
Size reduction of solids by milling is the oldest method to obtain small particles and is a basic 
operation in the processing of many powdered pharmaceutical excipients or drugs. 
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Nevertheless, for the production of protein microparticles these techniques are applied quite 
rarely until now. 
 
Jet milling 
Micronization by jet milling is the most common method to produce particles in the lower 
micrometer range. In brief, the raw material with a maximum size of about 1 to 2 mm is 
introduced into the milling chamber via a gas stream. Within the milling chamber a circular 
gas stream accelerates the particles which are micronized by collision with each other or with 
the wall of the chamber. The ground particles are removed from the milling chamber by the 
gas stream, while the larger ones stay inside due to centrifugal forces. 
Platz et al. described the jet milling of different proteins after freeze drying [81]. After 
micronization of human growth hormone 40 % of the powder was insoluble in water. It was 
possible to reduce this fraction to 2.5 to 7.5 % by exchanging some silver soldered joints and 
copper gas lines with more inert materials like stainless steel. Interferone-β was freeze dried 
with different mixtures of human serum albumin, NaCl and sorbitol. 50 % of the micronized 
particles were smaller than 3 µm and the mixture containing the sorbitol withstood the milling 
without significant loss of activity while the activity of the other mixtures was reduced by 
about 35 %. For granulocyte-colony stimulating factor soluble aggregates were detected after 
jet milling. Adding sorbitol to the protein solution before freeze drying reduced these 
aggregates to less than 4 %. By using HPLC no degradation of the protein was visible. 
Phillips et al. investigated the effect of the milling pressure on 5 amorphous proteins and 
peptides [82]. The improvement in size reduction by increasing the pressure was visible for all 
proteins but the dimension of the effect was different. For all tested materials mean particle 
sizes between 1.5 and 3.5 µm were measured. No impact on initial or long term storage 
stability or on the bioactivity was determined. 
Horseradish peroxidase was jet milled after co-precipitation with carbomer [83]. The activity 
of the protein was significantly reduced by the milling process, but the author stated that the 
way of co-precipitation had a much greater effect on protein stability than the milling process 
itself. It is worth while mentioning that after grinding the powder for 10 min in a mortar 
nearly no remaining activity of the peroxidase was measurable. 
Insulin was micronized in combination with sodium caprate as an absorption enhancer for 
pulmonary application [84]. The mixture was milled down to an average size of 2 µm and 
significant plasma insulin levels of insulin and a drop in glucose concentration were measured 
after pulmonary application to five dogs. Similar results were found for the pulmonary 
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activity of salmon calcitonin which was micronized after freeze drying with lactose and 
absorption enhancers. Particle sizes of 4 µm were achieved and significant blood levels of 
calcitonin were determined within rats [85]. 
Jet milling is besides spray drying the gold standard for the production of inhalable particles 
of small molecular drugs. For the processing of proteins and peptides the results are quite 
different and the reasons for the loss of activity of some proteins is not clear yet and has to be 
further investigated before it will be regularly used for these substances, too. 
 
Tribomechanical milling 
Tribomechanics is a field in physics which deals with phenomena occurring during fine 
milling under dynamic conditions. The milling equipment consists of two rotor discs placed 
against each other. On each disc several concentric rings of metal teeth are placed. During the 
milling process the discs rotate in opposite directions (10.000 – 22.000 rpm) while the product 
enters the center of the discs via an air stream. By collision and friction size reduction takes 
place. 
The system was tested in food industry on different whey protein powders with 60 % (WPC-
60) respectively 80 % (WPC-80) protein content at a feed rate of 5 kg/min and rotor speeds 
between 16.000 and 22.000 rpm [86]. The resulting particle size decreased with increasing 
rotor speeds. For WPC-60 the average size was reduced from 59.7 µm to 13.3 – 17.8 µm and 
for the WPC-80 from 76.7 µm down to 45.1 – 46.6 µm. While solubility of the WPC-60 
powder in water increased even a little bit from 88 % to about 90 % the solubility of the 
WPC-80 powder with the higher protein content decreased from 85 % to about 76 %. 
Additionally changes in the rheological properties of the milled powder were determined [87]. 
For pharmaceutical applications the size reduction potential is not high enough and the 
changes in protein integrity have to be further investigated. Furthermore, the needed amounts 
of powder are very large and not practicable for the small amount of expensive protein drugs. 
 
Media pearl milling 
In this process a liquid is used as a medium during milling. A rotating milling chamber is 
filled with small pearls with a diameter of 0.6 to 1.1 mm. The protein is suspended in the 
liquid and circulates from a reservoir to the milling chamber. In most cases the whole setup 
was combined with a cryostat for cooling. 
Lizio et al. micronized cetrorelix acetate suspended in heptafluoropropane (HFA 227) [88]. 
The milling chamber and pearls were provided with abrasion resistant materials, such as 
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iridium-stabilized ZrO2. During the process the system was cooled down to -44°C or -60°C. 
Resulting cetrorelix particles had an average diameter of 2.1 µm and were absolutely stable 
under the used conditions. Due to the modified materials no contaminants from the process 
were detected. 
Irngartinger et al. performed also experiments with cetrorelix acetat with nearly the same 
setup [26]. The milling setup was cooled down to -70°C by using ethanol 96 % as coolant. 
Particles with a diameter of 1.58 µm were obtained and again no degradation products could 
be determined. 
This process seems to be useful to directly produce suitable suspensions for pressurized 
metered dose inhalers. For other applications the use of a dispersion medium may be a 
disadvantage. 
 
High pressure homogenization 
High pressure homogenization is a well known method for the preparation of stable 
nanoemulsions [89] and nanosuspensions [90] or for the preparation of solid lipid 
nanoparticles [91]. A disperse system (emulsion or suspension) is forced through a small slit 
by applying high pressure up to 1500 bar. During the passage of the small slit the dynamic 
pressure increases while the static pressure decreases, which was described by Bernoulli. If 
the static pressure falls below the vapor pressure of the liquid it begins to boil. Behind the slit 
the static pressure suddenly increases and the small gas bubbles implode. This cavitation 
effect originates high forces which disrupt the emulsion droplets or solid particles. 
Maschke et al. tested this process for the micronization of insulin suspended in miglyol
®
812 
[92]. The insulin crystals were micronized at different pressures and the homogenization 
process was repeated up to 6 homogenization cycles. The average particle size was reduced 
from 15.8 µm to 3.7 µm after homogenizing 6 times at 1500 bar. By HPLS-MS no 
degradation products were visible and full bioactivity was determined in a chondrocyte 
proliferation assay. 
The results for insulin are promising, but results for other more sensitive proteins have to be 
determined before the process can be finally evaluated.  
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Summary 
For the production of small protein particles numerous methods and techniques were 
developed or modified. Achieving the desired particle sizes and size distributions does not 
seem to be the major problem, maintaining protein stability and bioactivity are the challenges. 
Adding excipients for the stabilization of sensitive proteins is the commonly used and good 
working solution at the moment. Each process has its own advantages and disadvantages and 
no method can really outrun the others. The use of organic solvents is always critical and has 
to be carefully evaluated to prevent contamination of the final product. Cost and time 
consumption are important factors which have an impact on the development, too. It also 
depends on the form in which your purchased protein is available. If it is a solution the on-
step methods may be favored and if it is already available as a powder it would be a good idea 
to avoid the critical dissolving step and process the powder directly. 
At the moment for each protein and each application it is more or less a trial and error process 
to find the optimal method. 
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Jet milling – theoretical background 
Jet milling is a well established micronization method and the process has been investigated 
since the 1950s and is besides hammer mills and ball mills the most often used technique for 
ultrafine grinding (<10 µm) [93]. So the principles of size reduction are well known for this 
method and it is applied to many different substances ranging from technical powders, like 
laser printer toner [94], to pharmaceutical drugs for pulmonary applications [95]. The often 
mentioned advantages are achievable particle sizes below 10 µm, very low risk of product 
contamination e.g. by attrition or lubricants and grinding of heat sensitive materials due to the 
cooling effect of the expanding gas stream. Nevertheless, only few results exist for the 
micronization of proteins. 
To understand the size reduction processes and identify important parameters, which may 
have an impact on the micronized product concerning particle size and stability, knowledge 
about the theoretical background is indispensable [96]. 
 
Assembly of a jet mill 
A jet mill consists of a cylindrical milling chamber with 4 to 8 nozzles implemented into its 
wall (fig. 1.2). The nozzles are symmetrically aligned with an angle between 52°-60° [97] so 
that a circular gas stream with high rotational speed results within the chamber, when pressure 
is applied. Additionally a feed injection nozzle is installed. Due to the existing negative 
relative pressure above the venturi nozzle the added powder is continuously introduced into 
the milling chamber with the gas stream. Inter-particle collisions and impact on the wall of the 
milling chamber are the size reduction mechanisms. The ground particles are carried out of 
the milling chamber with the gas stream and are collected in a cyclone separator. It is a main 
difference to other grinding methods that jet mills contain no moving parts, which reduces the 
risk of product contamination by attrition or by lubricants. 
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Fig.1.2: Milling chamber of a jet mill: (1) Nozzle, (2) gas outlet, (3) grinding zone, (4) separation 
zone, (5) circular gas stream, (6) jet of gas out of nozzles (dotted line) 
 
 
Particles in a gas stream 
The principle of micronization by jet milling is the collision of particles within a fast gas jet. 
The processes responsible for size reduction and separation within the milling chamber were 
investigated intensively in the 1960s by Rumpf and Kuerten [98,99]. By using 
triboluminescent substances like sucrose it was possible to have a closer look on the size 
reduction mechanisms. Triboluminescent substances emit light during size reduction due to 
the formation of an electrical field between the breakage surfaces. The light emission pattern 
during the milling process was analyzed by using a transparent milling chamber. Figure 1.2 
illustrates the different detected areas in a milling chamber during the milling process. 
Size reduction mainly takes place at the backside of the gas streams coming out of the 
nozzles. Due to the circular motion of gas within the milling chamber, these jets are deformed 
(fig. 1.3) and within the resulting vortices at the backside, the probability of collisions of 
particles with different relative velocities dramatically increases.  
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Fig. 1.3: jet of gas in a cross flow (adapted from Abramovich [100]) (1) cross flow, (2) gas jet out of 
nozzle, (3) vortical gas streams 
 
For size reduction special prerequisites for collisions have to be fulfilled and the relative 
velocities of the colliding particles have to be large enough. Collisions are possible if the 
average free path length (averaged distance between two single particles) between the 
particles is smaller than their flight path length (distance the particle will fly starting with a 
specific velocity taking air resistance into account). If you start from the assumption that the 
velocity of the particles is spatial equally distributed within the chamber, the average free path 
length can be calculated by equation 1.1: 
 
𝝀 ≈
𝒙
𝟏𝟎∗(𝟏−𝒒)
          (1.1) 
 
[𝜆 ] = 𝑚  average free path length 
 𝑥 = 𝑚  particle diameter 
𝑞   particle free volume portion on chamber volume 
 
Flight path length of particles is described by equation 1.2 [101]: 
 
𝒔𝟎 =
𝒙𝟐∗𝝆𝒔∗𝝂𝟎
𝟏𝟖∗𝜼
          (1.2) 
 
[𝑠0] = 𝑚  flight path length 
 𝑥 = 𝑚  particle diameter 
[𝜌𝑠] = 𝑘𝑔 ∗ 𝑚
−3 density of solid 
1
2
3
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 𝜈0 = 𝑚 ∗  𝑠
−1 particle velocity at time zero 
 𝜂 = 𝑃𝑎 ∗  𝑠 dynamic viscosity of milling gas 
 
Fig. 1.4 shows average free path lengths and flight path length depending on particle size at 
different typical velocities and loading of the milling chamber for jet milling. 
 
 
Fig. 1.4: maximal flight path length (S0) and average free path length (   ) depending on the size x of 
spherical particles (ρ=1 g/cm3) in air (20°C) [102] 
 
It becomes obvious that there is a natural grinding limit by using jet milling. If the flight path 
length gets shorter than the average free path length, no collisions will take place or the 
velocities are much too low to initiate particle breakage. For typical conditions in a jet mill the 
grinding limit is at about 0.1 to 1 µm, depending on the applied pressure, type of milling gas 
and used substance. The grinding process is influenced by the frequency of collisions and the 
intensity of these collisions. Therefore, the results depend on the concentration of solid in the 
milling chamber and on the impact velocity. Hence, the feed rate is an important parameter to 
facilitate a successful milling process. It has to be high enough to allow inter-particle 
collisions, but if it is too high, on the one side the acceleration before impact is too short and 
on the other side the gas stream is slowed down and the milling process is not efficient. 
In the center of the circular milling chamber you find the separation area (fig. 1.2 (4)). 
Particles are affected by the gas flow, which leaves the chamber, and by occurring centrifugal 
forces. The gas stream leads the particles to the center of the milling chamber to the outlet 
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opening, while the centrifugal forces resulting from the circular motion push the particles to 
the periphery. Theoretically a particle size limit can be calculated where 50 % of particles 
leave the milling chamber, while the other 50 % stay within the milling chamber for further 
micronization. Assuming laminar flow around the particles the drag force can be expressed by 
the equation of Stokes [103]. This leads to the following equation (3) for this size limit [104]: 
 
𝒙𝒍𝒊𝒎 =  
𝟏𝟖∗𝜼∗𝝂𝒓∗𝒓𝒊
 𝝆𝒔−𝝆𝒈 ∗𝒖𝒊
𝟐         (1.3) 
 
[𝑥𝑙𝑖𝑚 ] = 𝑚  particle size limit 
 𝜂 = 𝑃𝑎 ∗ 𝑠 dynamic viscosity of milling gas 
 𝜈𝑟 = 𝑚 ∗ 𝑠
−1 radial velocity 
 𝑟𝑖 = 𝑚  radius 
[𝜌𝑠] = 𝑘𝑔 ∗  𝑚
−3 density of solid 
 𝜌𝑔 = 𝑘𝑔 ∗ 𝑚
−3 density of milling gas 
 𝑢𝑖 = 𝑚 ∗ 𝑠
−1 circumferential speed at a circle of radius ri 
 
Based on this process small particles below the limit are removed out of the milling chamber, 
while large ones are hold back for further grinding. Therefore, jet milling results in narrow 
particle size distributions as milling and size fractioning are combined in one process. This 
separation mechanism however, is influenced by the angle of the nozzles in the milling 
chamber; the particle size limit is lowered with higher circumferential speed and with lower 
radial velocity at the outlet. A compromise has to be found between large angles, which allow 
good acceleration of the particles, and low angles, which are necessary for a good separation 
step [96]. Angles between 52° and 60° were found to be optimal for jet mill grinding [97]. 
 
Particle breakage 
As mentioned before, the prerequisites for particle collisions must be fulfilled to facilitate size 
reduction, but not every collision results in breakage of the two particles. Conditions for and 
processes during particle breakage will be described in the following part. 
The powder particles are accelerated by the gas stream. When collisions with other particles 
take place, elastic deformations are the consequence. Thus tension areas are induced, which 
concentrate on small cracks or flaws within the particle. If the tension exceeds a critical value 
crack extension occurs. It was demonstrated that treating particles with blasts before 
Chapter 1 Introduction and Goals of the Thesis 
26 
micronization enhances the milling result by inducing microcracks [105], proving the 
importance of these flaws for particle breakage. 
Two prerequisites have to be fulfilled that particle breakage takes place: the differential and 
the integral breakage condition [106]. To start the fracture the crack extension force must 
exceed the surface energy of the created surfaces (differential breakage condition). The crack 
is only able to propagate through the whole particle if the complete needed energy is stored 
within the tension field (integral breakage condition), because the crack propagation is so fast 
that no further energy can be supplied from the surrounding. 
In practice however, the needed fracture energy is orders of magnitude larger than the surface 
energy of the just created surface areas. Most of the applied energy is consumed by structural 
changes, kinetic energy of the formed fragments, emission of light (triboluminescence) and 
heat consumption. Especially during crack propagation high temperatures may occur at the 
new created surfaces. For ground glass up to 3200 K were measured at the breakage area 
[107]. After the propagation of the crack however, the surfaces cool down very rapidly within 
less than 10
-6
 seconds [108] 
 
Grinding limit 
As described before, one limiting factor for particle size reduction by jet milling is dependent 
on average free path length and flight path length, which determines the likelihood of 
collisions. Another limiting factor is the particle size itself. The smaller the particles the 
smaller is the probability of cracks and flaws, which are essential prerequisites for particle 
breakage. Therefore, it can be observed, that the particle strength increases while the particle 
size decreases, which can be explained by more and more perfect crystal structures. The 
particle strength is defined as the ratio of the force acting on the particle at the breakage point 
divided by a nominal particle cross-section [109]. For example, the particle strength of a 
10 µm quartz particle is 350 MPa. This value raises up to 800 MPa for a 5 µm particle. 
Another reason for this size depending effect is that the particles have to be big enough to 
store the elastic energy needed for the particle breakage. The critical size is described by 
equation (1.4) [108]: 
 
𝒍 ≥
𝜷
𝑾𝒃𝑽
=
𝟐∗𝒆∗𝜷
𝝈𝒃
𝟐           (1.4) 
 
 𝛽 = 𝐽 ∗  𝑚−2 surface energy 
 𝑙 = 𝑚  particle size 
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 𝑊𝑏𝑉  = 𝐽 𝑚
−3 breakage energy related to the volume 
 𝑒 = 𝐽 𝑚−3  Young´s modulus 
 𝜎𝑏  = 𝐽 𝑚
−3  breakage tension 
 
For most particles this limit is below one micrometer, but often instant reagglomeration takes 
place increasing the measured particle sizes [106]. 
 
Predicting particle sizes after the milling process 
Three factors determine the milling behavior of a substance: the mechanical properties of the 
material, the initial particle size distribution of the powder and the chosen milling conditions 
[110]. However, the mechanical properties of the material and depending on that the specific 
energy consumption for breakage are hard to determine. They depend on a lot of factors like 
Young´s modulus, hardness, number of cracks and flaws. Therefore, the energy consumption 
can hardly be estimated and no exact efficiency factor is available for jet mill grinding. It is 
estimated that only 0.05 to 2 % of the energy supplied by the milling gas are used for the size 
reduction process [111]. At the moment there are still no methods, which allow a good 
prediction of milling behavior of particles based on material properties and milling technique. 
For that reason a lot of effort has to be put in the optimization of milling processes of new or 
unknown powders. 
Different approaches were undertaken to formulate a ―law of comminution‖. The three most 
known ones are the hypotheses of Rittinger (1867) (eq. 1.5), Kick (1855) (eq. 1.6) and Bond 
(1951) (eq. 1.7) [112,113]. 
 
𝑾𝑹𝒊𝒕𝒕𝒊𝒏𝒈𝒆𝒓 = 𝒄𝑹 ∗  
𝟏
𝒅𝒑
−
𝟏
𝒅𝒇
         (1.5) 
𝑾𝑲𝒊𝒄𝒌 = 𝒄𝑲 ∗ 𝐥𝐨𝐠  
𝒅𝒇
𝒅𝒑
          (1.6) 
𝑾𝑩𝒐𝒏𝒅 = 𝒄𝑩 ∗   
𝟏
𝒅𝒑
−  
𝟏
𝒅𝒇
         (1.7) 
 
 𝑊𝑥 = 𝐽 ∗  𝑘𝑔
−1 specific grinding energy 
 𝑐𝑥    constant of the material concerned, work indices 
 𝑑𝑓 = 𝑚  size of feed 
 𝑑𝑝 = 𝑚  size of product 
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These ―laws of comminution‖ are useful tools for the extrapolation of milling results, but their 
scope is limited and the best-fitting equation has to be chosen for each single experimental 
setup. The material constants have to be determined experimentally, which means a lot of 
effort. A large list exists for the Bond work indices, which is the reason why it is the most 
popular one of these three hypotheses [114]. Nevertheless, no exact estimations of the 
grinding energy are available until now, which is certainly attributed to the fact that energy 
loss occurs throughout all milling processes, what is not taken into account for these 
estimations. 
Due to this gap, a field of research formed to solve this problem starting from a theoretical 
statistical approach. Nearly all of them are based on two different processes. First, the 
―selection function‖ that describes the fraction of particles destroyed in an experiment. 
Second, the ―breakage function‖ describing the size distribution of the fragments after 
breakage, not considering the undestroyed particles [115]. Again the main problem is to find 
easy ways of obtaining all necessary particle properties like size of initial flaws, hardness or 
surface energy. 
Several groups are working in this field [110,115–119]. The results are quite promising, but 
the transfer to practical applications in pharmaceutical industry will take a longer time. 
Therefore, still experimental optimization has to be performed for every new substance or 
machine. A possibility to reduce time and costs for these experiments may be the utilization 
of statistical experimental design, which is used for process optimization in many other fields. 
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Goals of the thesis 
To meet the demand of the pharmaceutical industry to process and deliver proteins in solid 
state it is necessary to establish methods, which allow a customized particle design. As 
abovementioned jet milling is one of the most effective micronization methods, but its 
potential for the micronization of proteins has not yet been tested to the full extend. Therefore, 
the aim of this thesis was to provide more information about the jet milling of proteins. For 
this investigation three important points have to be considered: 
 
1. Which particle size distributions can be obtained by jet milling and is there a difference 
between different proteins? 
2. Which are the important process parameters and how can the process be optimized to 
improve the size reduction and size distribution? 
3. Are there any negative effects on stability or activity of the investigated proteins due to the 
milling process? 
 
To address these questions, first of all the setup of the jet mill had to be optimized. One big 
problem was to deal with the air humidity in standard lab environment. It is well known that it 
leads to agglomeration of micronized particles (e.g. powdered sugar) and also may influence 
the activity and stability of processed proteins [120]. Additionally a cryogenic grinding setup 
as an additional investigated parameter had to be developed and evaluated, which also 
reinforces the need for the exclusion of humidity. These customization steps are described in 
chapter 3. 
As mentioned before, many pharmaceutical applications demand protein particle sizes below 
10 µm. For many of the low molecular weight drugs this is performed by jet milling, but for 
protein drugs only very few investigations exist. Are there detectable differences between 
different proteins? Are crystalline or amorphous proteins micronized differently? These 
questions were investigated by using three model proteins with known properties and 
different characteristics: bovine insulin, hen egg white lysozyme and bovine serum albumin. 
Their size distributions were analyzed after milling by laser light diffraction analysis and were 
verified by scanning electron microscopy of the resulting protein powder. The effect of 
milling pressure, number of milling cycles and of the milling gas temperature on the resulting 
particle size was analyzed by using statistical experimental design (chapter 4). 
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Nevertheless, particle size is only one important parameter. For proteins the conservation of 
chemical and structural stability and of their bioactivity is even more important. Therefore, 
the proteins were analyzed for changes after the milling process by HPLC, MALDI ToF, CD-
and fluorescence spectroscopy. Lysozyme and insulin were chosen as model proteins, because 
for both well established bioactivity assays are available. The bioactivity of insulin was tested 
in cell culture experiments, where the dose dependent effect of insulin on the proliferation and 
quality of the extracellular matrix of chondrocytes was utilized (chapter 5). The enzymatic 
activity of lysozyme was tested by using the well established micrococcus assay (chapter 6). 
For BSA, chosen because of its wide spread use and higher molecular weight, it occurred that 
changes in its solubility in water were the most prominent altered property due to the jet 
milling process and the main hurdle for further investigations (chapter 7). If it was possible, 
the effects of the micronization process on the investigated parameters of the proteins would 
be analyzed by using the statistical experimental design to identify the impact of the single 
milling parameters. 
Inspired by different methods for the preparation of lipid microparticles, like solvent 
evaporation and spray congealing methods and difficulties to obtain small and homogeneous 
distributed particles, the suitability of jet milling for this task was tested. Additionally the easy 
measurable heat effects on lipid powders were utilized to get a closer look on the impact of jet 
milling on heat sensitive substances. Glycerol tripalmitate (Dynasan 116
®
) was jet milled at 
different conditions and afterwards characterized by laser light diffraction, scanning electron 
microscopy and DSC measurements (chapter 8). 
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Materials  
Bovine insulin crystals were a gift from Sanofi-Aventis (Frankfurt, Germany), chicken egg 
white lysozyme lyophilized powder, albumin from bovine serum (BSA), albumin from bovine 
serum essentially fatty acid free, l-glutathione oxidized and l-glutathione reduced were 
purchased from Sigma Aldrich (Taufkirchen, Germany). We acquired the HPLC-grade 
acetonitrile from Baxter (Deventer, The Netherlands), trifluoroacetic acid (TFA) from Riedel-
De-Haen (Sigma Aldrich, Taufkirchen, Germany) and isobutanol from Merck-Schuchardt 
(Hohenbrunn, Germany). Water was double-distilled and filtered through a cellulose nitrate 
filter (pore size 0.2 µm, from Sartorius, Göttingen, Germany) prior to use. Glycerol 
tripalmitate (Dynasan116
®
) was purchased from Sasol AG (Witten, Germany). Thrombin was 
provided by Baxter (Unterschleißheim, Germany) and bovine fibrinogen, lyophilized 
micrococcus lysodeikticus cells ATCC No. 4698, calcium chloride, potassiumphosphat 
buffer, 8-anilino-1-naphtalenesolfonic acid ammonium salt (ANS), Ellman´s reagent 5,5´-
dithiobis(2-nitrobenzoic acid) (DTNB) and dieethylenetriamine-pentacetic acid (Detapac) 
were purchased from Sigma-Aldrich (Taufkirchen, Germany). Knee joints from 3-month-old 
bovine calves were obtained from a local abattoir within 12–18 h of slaughter. Type II 
collagenase and papainase were purchased from Worthington (CellSystem, St. Katharinen, 
Germany). Dulbecco's Modified Eagle's Medium (DMEM) with 4.5 g/l glucose, fetal bovine 
serum (FBS), MEM non-essential amino acid solution, penicillin, streptomycin, HEPES 
buffer, and phosphate buffer solution (PBS) were obtained from Gibco (Karlsruhe, Germany). 
149 μm pore size polypropylene filters were purchased from Spectrum (Rancho Dominguez, 
CA, USA). Hoechst 33258 dye was obtained from Polysciences (Warrington, PA, USA). All 
cell culture plastics were purchased from Corning Costar (Bodenheim, Germany). 
 
Methods 
Storage of sugar at 75 % rel. humidity 
In order to store micronized sugar exactly at 75 % rel. humidity a saturated sodium chloride 
solution was prepared in a chromatography chamber. The humidity was allowed to equilibrate 
for one day. The open vial with the micronized sugar was inserted in the chamber and stored 
for one day. Afterwards the sugar was dried under vacuum and SEM pictures were taken. 
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Micronization of proteins by jet milling 
For micronization a modified MC One® jet mill (Jetpharma, Balerna, Switzerland) was used. 
The mill was equipped with a custom made cryogenic cooling device and a temperature 
measurement unit (N9001 thermometer with air temperature sensor, Comark Limited, 
Stevanage, UK). For cryogenic grinding the milling gas was piped through a coiled tube 
inserted into a dewar vessel filled with liquid nitrogen. Therefore, it was possible to cool the 
milling gas down to approximately -60°C. Temperature of milling gas was measured within 
the gas stream shortly behind the milling chamber. To exclude effects of air humidity [121], 
the complete experimental setup was integrated in an isolator filled with dry nitrogen 
atmosphere (RH <2 %; hygrometer testo 608-H2, Testo, Lenzkirch, Germany). Nitrogen with 
a purity of 99.999 % was used as the milling gas. For each experiment 500 mg of protein was 
micronized. The milling pressure ranged from 6 to 14 bar (the feeding pressure was kept 1 bar 
above to prevent blow back of the powder). The feeding rate was kept constant at a rate of 
120 mg/min for all experiments to allow milling at all used milling pressures without 
accommodating the feed rate. 
 
Micronization of glycerol tripalmitate 
Before micronization glycerol tripalmitate was carefully ground by using an agate mortar and 
was sieved through a 1000 µm mesh to obtain particles which were able to pass the feed 
opening of the jet mill. 600 mg of were fed to the mill (120 mg/min) and ground at different 
milling pressures. 
 
Experimental design 
A full factorial face centered central composite design (CCF) was performed to investigate the 
effect of three different process parameters on resulting particle size. The effects of milling 
pressure, number of milling cycles and temperature of the milling gas were analyzed. Milling 
pressure and number of milling cycles were investigated on three levels. Milling gas 
temperature was defined as an uncontrolled factor to take fluctuations during different cycles 
into account. Table I provides a survey of the varied parameters and conditions. Overall, 22 
individual experiments were performed for each protein (table 2.1); the first half at room 
temperature, the second part of experiments at about -60°C. Coefficients based on quadratic 
polynomial equation (2.1) were estimated by using Partial least Squares (PLS) fitting. 
 
y=b0+b1x1+b2x2+b3x3+b4x1
2
+b5x2
2
+b6x3
2
+b7x1x2+b8x1x3+b9x2x3+ε   (2.1) 
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table 2.1 parameters of the experimental design 
 
Where y represents the investigated response, b0 the constant part of the term, b1-b3 the linear, 
b4-b6 the quadratic and b7-b9 the interaction coefficients and ε the error. The PC software 
MODDE 7.0.0.1 (Umetrics, Umea, Sweden) was used to both generate the experimental 
design and analyze the resulting data. The influences of the scaled and centered coefficients of 
equation (1) were investigated by using an F-Test at a confidence interval of 0.95. A 
coefficient was recognized as having an effect on the response (d90 value) if it was 
significantly different from zero. The insignificant terms were excluded from the model and 
the coefficients were recalculated. 
 
Particle size determination 
Protein particles 
The protein particles were suspended in 18 ml degassed isobutanol (refractive index 1.39) and 
particle size distribution was measured using a Mastersizer 2000 (Malvern Instruments, 
Herrenberg, Germany) equipped with a Hydro 2000µP dispersion unit. Mie scattering theory 
was used to calculate particle sizes (insulin refractive index 1.54, absorption 0.1 [92], BSA 
and lysozyme refractive index 1.55, absorption 0.01 [122]). For disaggregation of 
agglomerates an integrated device was used to apply ultrasound (48 kHz, 20 W) for ten 
seconds before measurement. Each sample was measured for 20 seconds and 5 measurements 
were averaged. As characteristic values for particle size distribution the d90 and d50 
(percentage of particles that are smaller than the given value) were analyzed as response 
parameters. 
Glycerol tripalmitate microparticles 
For lipid microparticles (refractive index 1.5, absorption 0) a Hydro S dispersion unit 
(Malvern Instruments, Herrenberg, Germany) was used. The particles were suspended in 
ethanol 68.2 % (V/V) (refractive index 1.361). The measurement was performed as described 
for the protein particles. 
 
Variable Level -1 Center point Level +1 
x1: milling pressure 6 bar 10 bar 14 bar 
x2: number of milling 
cycles 
1 2 3 
x3: cooling device on 
(approx. -60°C) 
 
off 
(room temperature) 
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Changes in particle size during storage of BSA 
To investigate if there is a change in particle size during the storage in the freezer, we 
measured the particle size of each sample of BSA directly after the micronization process and 
after four weeks of storage in the freezer at about -20°C under nitrogen atmosphere by using 
the described protocol for the size measurement by laser light diffraction. 
 
Morphology of micronized particles 
Pictures were taken by using a scanning electron microscope (JSM 840; Jeol, Japan) at 3kV. 
The particles were fixed on aluminum stups using conductive carbon tape (LeitTabs; Plannet 
GmbH, Germany) and coated with gold by sputtering three times for 20 seconds (SEM 
Autocoating unit E2500; Polaron equipment LTD, UK). 
 
HPLC analysis of the model proteins 
All proteins and peptides were analyzed for changes due to the micronization process by 
HPLC. A HPLC System with a degasser (Knauer, Berlin, Germany), LC-10AT pump, FCV-
10ATvp gradient mixer, SIL-10Advp autosampler, CTO-6a oven, SPD-10AV UV-Detector, 
RF-551 fluorescence detector and SCL-10Avp controller (all from Shimadzu, Duisburg, 
Germany) and a C18-reversed phase precolumn (LC318, 4.6x20 mm; Supelco, Bellefonte, 
USA) combined with an analytical C18-reversed phase column (Supelcosil, LC318, 
4.6x250 mm; Supelco) was used. 
Insulin 
Chemical stability of bovine insulin was determined by a previously described method [92]. 
One milligram of insulin was dissolved in 1 ml 0.01 M HCl. 50 µl of this solution were 
injected into the HPLC system at 37°C. During measurement, a linear gradient was applied 
(mobile phase A: 90 % H2O, 10 % acetonitrile, 0.1 % TFA; mobile phase B: 90 % 
acetonitrile, 10 % H2O and 0.1 % TFA; flow rate of 1 ml/min). The fraction of phase B was 
increased from 20 % to 36 % over 22 min (total run time 30 min). Signals were recorded 
using UV detection (210 nm and 274 nm). 
Lysozyme 
One milligram of lysozyme was dissolved in 1 ml bidistilled water. 50 µl were injected into 
the HPLC system at 40°C. The same mobile phases as for insulin were used, but phase B 
changed from 25 % to 40 % over 35 min (total run time 40 min). Signals were recorded using 
UV detection (210 nm and 274 nm). 
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BSA 
Five milligrams of BSA were dissolved in 1 ml bidistilled water. 50 µl were injected into the 
HPLC system at 40°C. Mobile phase A consists of water and 0.1 % TFA, phase B of 90 % 
acetonitrile, 10 % water and 0.1 % TFA. The analytical run started with 3 min with 27 % of 
phase B. Afterwards the fraction of phase B was increased from 27 % to 54 % over 12 min. 
The concentration was kept at this concentration for additional 10 min. Signals were recorded 
using UV detection (210 nm and 274 nm). 
GSH 
2.5 milligrams of GSH were dissolved in 1 ml bidistilled water. 50 µl were injected into the 
HPLC system at 40°C. Mobile phase A consists of water and 0.1 % TFA, phase B of 90 % 
acetonitrile, 10 % water and 0.1 % TFA. The analytical run started with 100 % phase A for 
3 min. Afterwards the fraction of phase B was increased to 20 % during 17 min and was kept 
at this concentration for 5 min. At the end phase B was reduced to 0 % in 1 min and the run 
was finished after total time of 30 min. Signals were recorded by UV absorption at 210 nm. 
 
MALDI analysis of insulin and lysozyme 
As matrix α-cyanohydroxy-cinnamic acid dissolved in 50 % acetonitrile and 0.1 % TFA was 
used. Protein was solved in 0.1 % TFA and diluted in the matrix to a concentration of 5 µM. 
Samples were analyzed with Maldi ToF/ToF (4700 Proteomics Analyzer; Applied 
biosystems, USA) in linear mode. 
 
Determination of insulin-bioactivity 
Bioactivity of three differently treated samples of micronized insulin were investigated using 
a three-dimensional chondrocyte cell culture system utilizing fibrin gels as a carrier as 
described elsewhere [123]. These groups are: insulin micronized three times at 6 bar at room 
temperature, insulin micronized three times at 14 bar at room temperature and insulin 
micronized three times with 14 bar with cool milling gas. Two groups one without insulin and 
one with untreated insulin were used as controls. For all groups three experiments were 
performed (n=3). The effect of the insulin samples on cell proliferation due to interaction with 
the IGF receptor was investigated. In brief, primary chondrocytes where isolated from the 
surface of the femoral patellar groove of a three-month-old bovine calve. The cartilage was 
enzymatically digested overnight in DMEM containing 4.5 g/l glucose, 10 % FBS, 584 mg/l 
glutamine, 0.1 mM MEM non-essential amino acids, 10 mM HEPES, 0.4 mM proline, 
50 mg/ml ascorbic acid, 50 U/ml penicillin, 50 mg/ml streptomycin, and 470 U/ml of type II 
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collagenase. The digest was repipetted, filtered through a 149 µm mesh, and washed three 
times with PBS. The cell number was determined using a hemocytometer. 1x10
-6
 freshly 
isolated chondrocytes were resuspended in a fibrinogen solution (fibrinogen 50 mg/ml, CaCl2 
20 mM at pH of 7.0). Gels were formed by adding the same volume of thrombin solution. 
Each resulting fibrin disc (diameter 5 mm, thickness 2 mm) was put in a six-well plate and 
covert with 4 ml culture media containing 0.5 or 2.5 µg/ml of each insulin (control without 
insulin). The constructs were cultivated for 5 weeks, changing culture media three times a 
week. Afterwards the cell-fibrin constructs were analyzed. The constructs were weighed 
(=wet weight) and cut in parts. One section of each construct was lyophilized, then digested 
with 1ml of a papainase solution (3.2 U/ml in buffer) for 18 h at 60°C and used for the 
determination of cell number. The cell number per construct was determined by measuring 
DNA content using Hoechst 33258 dye [124]. Another section of each construct was 
successively fixed with a mixture of glutaraldehyde and formaldehyde for histological 
analysis. The samples were embedded in paraffin and cross-sectioned into 5 µm sections. 
After deparaffinization sections were stained with safranin-O. 
 
Determination of lysozyme-bioactivity 
The activity of lysozyme was analyzed using a method described by Shugar [125]. Lysozyme 
was dissolved in 66 mM potassiumphosphat buffer at pH 6.24. 100 µl of this solution were 
mixed with 2.5 ml cell suspension of micrococcus lysodeicticus. The decrease in absorption at 
450 nm wavelength due to lyses of the cells was measured in 12 second-intervals for 1 min 
(Uvikon; Kontron Instruments, UK). The kinetic rate, indicating the enzyme activity, was 
obtained from the slope of the linear part of the curve. Activity was calculated using a 
calibration curve measured with a solution of unprocessed lysozyme of the same batch. 
Additionally some samples were tested in the presence of 1 mM Detapac to complex possibly 
present iron. 
 
Obtaining lysozyme crystals 
In order to obtain lysozyme crystals a batch crystallization method described by Elkordy et al. 
[49] was used. 4 g of lysozyme were dissolved in 100 ml of 0.1M sodium acetat buffer 
pH 4.6. In another bottle 100 ml of a 10% sodium chloride solution were prepared. Both 
solutions were filtered using a sterile filter with pores of 0.2 µm. After mixing both solutions 
the mixture was stored for 24 h in the fridge at 4°C. Then the suspension was filtered by using 
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a 0.4 µm filter and the remainder was washed with isopropanol. Afterwards it was dried in the 
glovebox at a rel. humidity <2% for 24 h. 
 
Determination of the water insoluble fraction of BSA 
For the solubility determination of BSA approximately 10 mg of the micronized BSA samples 
were weighed into eppendorf cups of known weight. For the PEG BSA mixtures an amount 
corresponding to approximately 10 mg of pure BSA was weighed into the cups. Afterwards 
2 ml of water were added. Every 20 min the cup was vortexed for 5 seconds. After one hour 
the mixture was centrifuged at 13 000 rpm for 10 min. The supernatant was removed and 1 ml 
water was added to the remainder. Every 10 min it was vortexed for 5 seconds. After 30 min 
it was centrifuged again. This step was repeated three times. Afterwards the remainder was 
freeze dried and the eppendorf cup was weighed again after this process. As control samples 
without BSA and with unprocessed BSA were used. 
 
Finding a solvent for the insoluble BSA fraction 
To perform further analysis of the insoluble fraction occurring after jet milling BSA a suitable 
solvent had to be found. 10 mg of the micronized BSA powder were mixed with 2 ml of a 
solvent or solvent mixture. Every 10 min it was homogenized on a vortex shaker for 10 s. 
After one hour the vessel was controlled for not dissolved particles. 
List of tested solvents: 
-water 
-isopropanol 
-ethanol 68 % 
-acetonitril 
-ethanol 68 %, acetonitril 1:1 
-89 % water, 10 % acetonitril, 1 % TFA 
-6 M urea 
-6 M guanidine HCl 
-0.1 % SDS 
-10 mM dithioreythritol + 1 mM EDTA 
-6 M urea + 10 mM dithioreythritol + 1 mM EDTA 
-6 M guanidine HCl + 10 mM dithioreythritol + 1 mM EDTA 
-0.1 % SDS + 10 mM dithioreythritol + 1 mM EDTA 
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Determiation of free sulfhydryl (SH) groups for BSA 
The experiment was performed analog to the description of Aitken and Learmonth [126]. 
Unprocessed BSA was dissolved in 0.1 N phosphate buffer pH 8 at a concentration of 
50 mg/ml. 3 ml of buffer were added into a cuvet. 100 µl of 10mM solution of Ellman´s 
reagent 5,5´-dithiobis(2-nitrobenzoic acid) (DTNB) were added. Finally 200 µl of the protein 
solution were added and the absorption of the anion (TNB
2-
) was measured at 412 nm. The 
concentration of thiols was calculated from the molar absorbance of the TNB anion 
(E412TNB
2-
 = 1.415*10
4
 cm
-1
M
-1
). 
 
Blocking the free sulfhydryl group of BSA  
The free sulfhydryl group of bovine serum albumin was alkylated with iodoacetamide 
according to a modified literature procedure [127]. The pH of a BSA solution (15 mg/ml) was 
raised to 8 with 0.1 N NaOH. The reaction vessel was covered with aluminum foil and then 
approximately 2 mol of iodoacetamide per mol of sulfhydryl were added. The mixture was 
allowed to react for one hour at room temperature, while stirred with a magnetic stirring bar. 
Afterwards the mixture was centrifuged in a Vivaspin 20
®
 vessel with a cutoff filter of 
30 000 Da at 4°C. The remainder was washed with water three times. A control group without 
the addition of iodoacetamide was analyzed, too, to evaluate the effect of the process on the 
protein. 
 
Co-lyophilization of BSA with PEG 
1 g of different ratios of PEG 10 000 and BSA were dissolved in 10 ml of bidistilled water. 
The solutions were frozen at -25°C within a benchtop freeze-dryer (Beta 2-16 with LMC-2 
system control, Christ, Osterode, Germany). Afterwards the frozen samples were freeze dried 
at 6°C and 0.12 mbar for 24 hours. For complete drying the temperature was increased to 
20°C for additional 6 hours. The vacuum was removed by filling the chamber with dry 
nitrogen. The samples were stored at -20°C for further analysis. 
 
Investigating changes in the secondary structure of insulin and lysozyme by CD 
spectroscopy 
To investigate changes in secondary structure of the proteins due to the micronization process 
circular dichroism spectroscopy (spectropolarimeter J-710, Jasco, Gross-Umstadt, Germany) 
was used. CD spectra of protein solutions (15 µM in 66mM phosphate buffer pH 6.24) were 
recorded 190 nm to 260 nm at a scanspeed of 20 nm/min and temperature of 22°C in a quartz 
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cuvette with 0.1 cm path length. Five measurements were accumulated to reduce noise. 
Afterwards the secondary structure composition was estimated by using the CDNN algorithm 
[128] (CD spectra deconvolution software CDNN 2.1). 
 
Measurement of intrinsic fluorescence 
Lysozyme and BSA (0.1 mM) were dissolved in 10 mM phosphate buffer at pH 6.2. 
Measurements were performed using a LS55 fluorescence spectrometer (PerkinElmer, 
Waltham, USA) at 295 nm (excitation wavelength, slit = 5 nm), 300 – 500 nm (emission 
wavelength, slit = 5 nm) and scanspeed of 10 nm/s. For insulin measurements a stock solution 
in 0.01 M hydrochloric acid was prepared, which was diluted with phosphate buffer to 
concentration of 0.1 mM. The excitation wavelength for insulin was 280 nm because it does 
not contain any tryptophan. Fluorescence emission spectra were measured in the range from 
290 to 450 nm. Four measurements were accumulated and the background measured with 
pure buffer was subtracted. 
For BSA a stock solution was prepared and the insoluble fraction was removed by 
centrifugation. Afterwards the concentration of BSA was determined by UV measurements at 
280 nm using solutions with known concentration as reference. 
 
Measurement of surface hydrophobicity 
A method described by Lechevalier et al. was used to determine the surface hydrophobicity of 
proteins [129]. ANS is a probe multiplying its fluorescence intensity when it is in a 
hydrophobic environment and is therefore often utilized to investigate surface properties of 
macromolecules in solution. Each sample was dissolved in phosphate buffer (10 mM, pH 7) at 
6 different concentrations in the range of 0.005 – 0.05%. Insulin was dissolved in 0.01 M 
hydrochloric acid before dilution in phosphate buffer. 15 µl of an 8 mM ANS solution were 
added to 1 ml protein solution. The maximal fluorescence intensity of ANS was measured for 
5 s at 470 nm emission wavelength (excitation at 390 nm). Excitation and emission slits were 
10 nm and a cutoff filter of 430 nm was used. The fluorescence intensity was plotted against 
the protein concentration and the slope was calculated by linear regression analysis as an 
index of protein surface hydrophobicity (PSH). The relative surface hydrophobicity (RSH) 
was calculated as follows: 
RSH = (PSH of sample)/(PSH of control) 
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Determination of iron content by inductively coupled plasma – optical emission 
spectroscopy (ICP-OES) 
ICP measurements were performed to investigate, whether there was an increase of iron 
content within the protein powder due to the micronization process. For these measurements a 
JY40+ from Jobin Yvon (Unterhaching, Germany) with argon as plasma gas (16 l/min) and as 
carrier gas (2 l/min) was used. A specific amount of lysozyme was dissolved in 10 ml water. 
Calibration of the instrument was performed by using iron(III)chloride standards of 1, 10 and 
100 ppm. 
 
FT-IR measurements 
For FT-IR measurements a Tensor 27 spectrometer (Bruker, Ettlingen, Germany) with a 
single reflection ATR unit (Harrik MVP, Harrik Scientific, New York, USA) was used. For 
measurement the not micronized samples were ground in an agate mortar while the 
micronized ones were used without further processing. The samples were measured from 
4000 – 600 cm-1 wave number. For each sample 100 interferograms were collected and 
averaged using a resolution of 4 cm
-1
. Second-derivative spectra were created using the OPUS 
4 software (Bruker, Ettlingen, Germany). Afterwards the data was transferred to GRAMS 8.0 
software (Thermo Fisher Scientific Inc.). With GRAMS, each spectrum was attenuated to the 
amide I region (1700 – 1610 cm-1), baseline corrected and normalized to an area of unity 
[130]. The area under each band was correlated to different protein secondary structures as 
described by Krimm et al. [131] 
 
Differential scanning calorimetric (DSC) measurements of micronized lipid 
Micronized lipid microparticles were analyzed for structural changes by differential scanning 
calorimetry (DSC 2920, TA Instruments, Alzenau, Germany). 2 to 4 mg of each sample were 
weighed into AutoDSC aluminium sample pans (TA Instruments, Alzenau, Germany) and 
sealed with the TA Instuments encapsulating press. An empty sealed pan served as reference. 
The samples were equilibrated for 10 min at -20°C and the measurement was performed 
applying a heating rate of 5 K/min up to 100°C.  
 
Statistics 
Data were analyzed by applying ANOVA and then Tukey´s test. All measurements were 
performed in triplicate. The design of experiment data was analyzed by using MODDE 
7.0.0.1 Software (Umetrics, Umea, Sweden). 
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Introduction 
As mentioned before, jet milling is a well established and common micronization method, but 
it is normally utilized for processing big amounts of powder, starting from several grams up to 
kilograms of substance. However, most therapeutic proteins are very potent drugs and on the 
other side often are a very expensive class of substances. Both factors are causing the fact that 
for the processing of solid proteins only small amounts are available for process tests. 
Therefore, a special milling setup had to be found to allow sensible processing of proteins. 
 
Basic setup of the jet mill 
Taking the typically low available amounts of proteins and high costs into account, it was 
aimed to work with as little protein as possible for the milling experiments. Therefore, a 
small, laboratory scale jet mill was purchased: MC One
®
, Jetpharma. The details of the mill 
are described in table 3.1 and the setup is schematically shown in fig. 3.1. 
 
diameter of milling chamber 3.34 cm 
number of nozzles 4 
diameter of nozzles 1 mm 
nozzle angle 55° 
material AISI stainless steel 316L 
metal contamination of product < 1 ppm 
milling pressure 6 – 12 bar 
max. volume flow 10.8 Nm
2
/h 
process gas temperature 0°C – 50°C 
batch size 0.2 – 100 g 
Tab. 1.1: Specifications of MC One
®
 by Jetpharma 
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Fig. 3.1: schematic diagram of the used  jet mill: (1) milling chamber, (2) product collection container 
with cyclone separator, (3) exhaust gas filtration unit, (4) product feed by venturi injector, (5) gas feed 
for venturi injector, (6) gas feed for milling chamber, (7) control device for applied pressure on 
milling chamber and venturi. 
 
It is a so-called ―pancake‖ mill regarding the flat circular milling chamber. The whole mill is 
made off stainless steel and completely decomposable for easy cleaning. The connections 
between the different parts are sealed by Teflon (PTFE) gaskets. Jetpharma specifies that 
small batch grinding down to 200 milligrams of powder is possible with good yield. 
Although, this setup seemed to be very good, some modifications had to be installed in order 
to optimize the setup for protein grinding. In chapter 1 the negative effect of grinding on some 
proteins is described and therefore, some additional parameters should be tested for their 
stabilizing effect on the investigated proteins. 
In consideration of the sensitive product it can be assumed that the high temperatures created 
on the particle surfaces by impact breakage [107] may have a negative effect on product 
stability and activity. Therefore, the effect of cryogenic grinding on proteins should be 
investigated. Cryogenic grinding is seldom used in pharmaceutical industry because of its 
high costs [132]. The main applications for cryogenic grinding are the milling of heat 
sensitive substances like plants for food industry [133], grinding of herbs for medicinal usage 
[134] or the milling of elastic, rubber-like substances [135] or recycling of rubber tires [136]. 
At low temperatures the brittleness of many elastic or ductile materials is dramatically 
increased thus the mechanical size reduction process is improved [137]. The major 
1
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disadvantages as mentioned before are the much higher costs due to the special equipment 
and the consumption of liquid nitrogen [138]. However, for proteins both mentioned 
advantages may be possible, so that the higher costs may be outweighed by a better grinding 
performance and more stable products. 
 
Cryogenic setup 
In order to facilitate cryogenic grinding by jet milling the temperature within the milling 
chamber had to be cooled down below -50°C e.g. by liquid nitrogen. The lower temperature 
limit of the integrated valves of the MC One
®
 is 0°C (tab. 1.1). Therefore, the cooling had to 
take place by bypassing the valves to assure safe work with the jet mill. For the remaining 
parts the low temperatures were not expected to be a problem, because they are made of steel 
and Teflon. 
The first idea was adding liquid nitrogen parallel to the product feed into the milling chamber 
(fig. 3.2). A tank containing liquid nitrogen was installed right next to the opening for the 
powder feed. Powder and liquid nitrogen were blown into the milling chamber by the venturi 
nozzle. 
 
Fig. 3.2: First cryogenic setup; (9) temperature sensor, (10) liquid nitrogen tank 
 
Measuring the milling gas temperature just behind the milling chamber (fig. 3.2(9)) results in 
a temperature of -20 to -30°C. Lower temperatures could not be obtained. A problem occurred 
10
9
 Customizing the Jet Mill Chapter 3 
47 
due to the fact that liquid nitrogen entered the milling chamber and evaporated there by 
disturbing the normal gas flow. For this reason results from this setup were not comparable 
with the experiments at room temperature, because possible differences may have been 
provoked by the temperature difference or by uncontrollable turbulences in the gas flow. 
To overcome these problems no liquid nitrogen was added into the mill, but the gas pipes for 
the milling chamber and the venturi injector were modified. The pipes were elongated and 
each fitted into liquid nitrogen-containing tanks (fig. 3.3). 
 
 
Fig. 3.3: second cryogenic setup. (11) Gas feed for milling chamber within liquid nitrogen tank, (12) 
gas feed for venturi injector within liquid nitrogen tank 
 
Testing the new setup at different milling pressures resulted in temperatures of about -60°C 
(fig. 3.4). Small temperature differences at the different pressures are due to the cooling effect 
of the expanding gas in the milling chamber, which is higher at higher pressures. 
11
12
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Fig. 3.4: milling gas temperatures at standard conditions compared to temperatures with use of the 
cryogenic setup at different milling pressures 
 
The next step was to exclude air humidity from the whole process to avoid negative effects on 
particle size due to agglomeration and on stability and activity of the micronized protein 
powder [120]. 
 
Excluding air humidity 
During this test phase the need for humidity exclusion got very prominent. Due to the cold 
temperatures humidity condensed not only on the cold machine parts but also on the 
micronized product. To investigate the effect of humidity on the resulting powder 500 mg of 
sugar as a cheap test substance was micronized. In order to exclude humidity from the product 
two options were tested. First, 10 ml of isobutanol were filled in the product collection 
container (fig. 3.1(2)), so that the product is directly collected in the particle size measurement 
media without any contact with the surrounding air. The second option was to integrate the 
whole jet mill setup in a glovebox filled with a dry nitrogen atmosphere (fig. 3.5). A 
hygrometer was installed within the glovebox to check the air humidity permanently. All 
experiments within the glovebox were performed at rel. humidity lower than 2 %. After 
micronization the samples were stored in a desiccator for one day. 
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Fig. 3.5: Cryogenic setup integrated into nitrogen filled glovebox. (13) glovebox, (14) nitrogen inlet, 
(15) nitrogen outlet, (16) hygrometer 
 
The product yield of the micronized sugar was about 80 %. Particle size measurements 
showed that even under non cryogenic conditions agglomeration due to humidity took place 
(fig. 3.6). After one day storage the sample collected in isobutanol showed a narrow size 
distribution with particle up to 27 µm (d90 6.7 µm). A small shift to higher sizes was visible 
for the samples micronized in the glovebox. Some particles up to 500 µm (d90 12.1 µm) were 
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detectable. Under normal ambient conditions a clear shift to higher particles sizes was 
detectable with a d90 value of 123 µm. This demonstrated the effect of humidity on the 
resulting particle size. 
 
 
Fig. 3.6: size distribution of sugar micronized under different conditions at 8 bar after 1 day storage 
in an desiccator 
 
To illustrate the consequences of air humidity on micronized sugar one sample was stored one 
day at 75 % rel humidity, was vacuum dried afterwards and SEM micrographs were taken 
(fig. 3.7). 
 
 
Fig. 3.7: SEM pictures of micronized sugar a) stored at dry conditions and b) stored at 75 % rel. 
humidity 
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The differences were obvious, no sharp edges were detectable anymore and the particle 
surfaces appeared very smooth. Single particles were still identifiable, but solid connections 
were formed. Due to the humidity the single particles visible in fig. 3.7 a) were irreversibly 
agglomerated (fig. 3.7 b)), which is a good explanation for the particle growth detected by 
laser light diffraction. However, for proteins not only agglomeration would be a problem, it is 
well known that humidity also results in degradation or denaturation of proteins [139,140]. 
Therefore, all the following experiments were performed with the milling setup integrated 
within the glovebox. 
 
Summary 
Overall a jet milling system was established, which allowed the micronization of very small 
batches down to 200 mg with yield of about 80 % and cryogenic grinding at temperatures of 
about -60°C. Air humidity was recognized as a critical factor for micronization processes; 
therefore, it was totally excluded from the whole milling process, so that no impact on particle 
sizes or stability and activity data of the proteins should be expected. 
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Introduction 
The most important outcomes for size reduction obviously are resulting particle size and size 
distribution of the product. Additionally, important factors for the suitability of such a process 
are controllability and reproducibility to guarantee unchanged quality of the product. 
But even if the process is well characterized, for establishing the processing of a new 
substance or class of substances the process has to be validated from scratch on. Different 
properties like hardness, density, brittleness, size etc. of a new material make the transfer of 
parameters of other substances very difficult. Therefore, the establishment of size reduction 
processes and defining the right parameters for a new substance is very time- and in most 
cases also substance-consuming. This is especially true by using the traditional COST 
approach (changing one separate factor at a time) to optimize a process and find the optimal 
adjustments of the variable parameters. Especially when interactions between the investigated 
parameters exist, the probability of indicating an optimum far from the real optimum is high 
[141]. 
To overcome this problem statistical factorial design, also called Design of Experiments 
(DoE), for the planning of the single experiments was developed. With this approach all 
relevant parameters are varied simultaneously. By optimizing the experimental setup it is 
possible to reduce the number of necessary experiments without significant loss of 
information. The obtained data can be analyzed to yield valid and objective conclusions for 
the investigated parameters and interactions can be revealed. In principle DoE can be applied 
for the optimization of all processes with process relevant parameters, which can be varied on 
specific levels. Because of these advantages this method was established in many kinds of 
different fields like biotechnology [142,143], material sciences [144] and engineering [145]. 
In spite of these advantages the progress in displacing the COST-approach is not that fast. 
However, even in new guidelines e.g. of the ICH these methods are incorporated [146]. 
Therefore, DoE was applied to investigate the jet milling process of proteins for the 
identification and optimization of important process parameters. The suitability of the process 
was investigated by processing three different model proteins: bovine insulin, hen egg-white 
lysozyme and bovine serum albumin (BSA). Differing in molecular weight, structure, particle 
size and particle morphology these well characterized proteins should give a good impression 
of the impact of jet milling on this class of drugs. A closer look on the characteristics of the 
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three substances will be given at the beginning of the following chapters 5 – 7, where the 
focus is on the impact of the micronization process on chemical stability, structure and 
bioactivity. 
In this chapter the influence of the three process parameters milling gas pressure, number of 
milling cycles and temperature of the milling gas on particle size, size distribution and particle 
morphology was investigated. 
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Results and Discussion 
Particle size and size distribution 
The yield of the proteins after one milling cycle starting with 500 mg was at about 83 %. 
After 3 cycles it was possible to regain 40 % of the initially applied amount. 
To investigate the efficiency of the micronization process the resulting particle size 
distribution of each milling experiment was determined. Milling gas pressure, number of 
milling cycles and temperature of the milling gas were varied on specific levels (tab. 4.1). 
Figures 4.1 to 4.3 show typical size distributions for the investigated proteins. Detailed 
information about the obtained sizes is shown in table 4.2 for each experiment. For all three 
proteins particle sizes drastically decreased and the process resulted in very narrow size 
distributions. Using one milling cycle at 6 bar the d90 value of insulin was reduced from 
30.19 µm to 6.13 µm and for three cycles at 14 bar 3.30 µm were achieved. The much larger 
and broader distributed lysozyme and BSA particles (d90 of 673.66 µm and 919 µm) were 
micronized to 8.56 µm by milling once at 6 bar and to 4.07 µm at 3x14 bar for lysozyme and 
to 21.5 µm and 6.48 µm for BSA respectively. A small rest of coarser particles after milling 
lysozyme and BSA one time at 6 bar was traceable (fig. 4.2 and 4.3), which is probably due to 
the larger particles of the bulk material. Nevertheless, most d50 values were in the range of 2 
to 5 µm. These sizes are comparable to results in other publications where mean particle sizes 
of 3 µm for IFN-β containing sorbitol [81], sizes between 1.5 and 3.5 µm for five different 
proteins and peptides [82] and 2 µm and 4 µm, respectively, for insulin and calcitonin [84] 
were determined after jet milling. For the model proteins higher pressure and more milling 
cycles led to smaller particle sizes. With higher pressure more energy was provided to the 
milling chamber likely contributing to the smaller particle sizes. The most effective milling 
cycle regarding size reduction was the first one. Additional grinding cycles only had a small 
impact on the d50 value but the d90 was further decreased indicating a narrower size 
distribution (see table 4.2). A prerequisite for breakages of particles by all milling processes 
are existing cracks and flaws within the particles. With decreasing particle size the probability 
of those imperfections is reduced [147]. Therefore, there is a so-called grinding limit where 
only plastic deformation and no further breakage can take place [148]. This limit seemed to be 
at a d90 between 3 and 5 µm for the investigated proteins using this experimental setup, 
which corresponds to the results in the other studies. Furthermore, the residence time of small 
particles within the milling chamber is much shorter than that of larger ones, because they are 
taken out of the milling chamber with the gas stream much faster while the larger ones are 
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held back by the centrifugal forces. In our study the slight differences between the tested 
proteins after the first milling cycle are likely due to the different particle sizes of the 
unprocessed bulk materials. These differences could not be totally removed after three milling 
cycles, which indicates that the results are also influenced by other parameters, which are 
specific for each protein.  
For lysozyme and BSA an effect of the milling gas temperature on the resulting particle size 
was measured. With cooling slightly larger particles were measured for lysozyme, but for 
BSA the cooling resulted in smaller particles. The effect of the low milling gas temperature 
on BSA is maybe due to an increased brittleness at these temperatures. This is the main reason 
for cryogenic grinding, a more efficient grinding of elastic, rubber-like materials. The cooling 
restricts the molecule flexibility and therefore stress cannot be reduced by stretching any 
more. The energy saved as elastic deformation is concentrated within a smaller area and the 
tension and also the fracture probability increased [149]. 
 
 
 
Variable Level -1 Center point Level +1 
x1: milling pressure  6 bar 10 bar 14 bar 
x2: number of milling 
cycles 
1 2 3 
x3: cooling device on 
(approx. -60°C) 
 off 
(room temperature) 
Tab. 4.1 parameters of the experimental design 
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Tab. 4.2 results of the micronization experiments  
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Fig. 4.1 size distributions of insulin micronized without cooling 
 
Fig. 4.2 size distributions of lysozyme micronized without cooling 
 
Fig. 4.3 size distribution of BSA after micronization without cooling  
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Particle morphology 
To verify the results measured by laser light diffraction SEM micrographs were taken from 
the micronized protein powders. SEM pictures (fig. 4.4, 4.5 and 4.6) show the protein 
particles before milling and after one micronization cycle at 6 and after three cycles at 14 bar 
without and with cooling. It is clearly visible that in spite of the very different morphology of 
the bulk material, after micronization the resulting particles look very similar. For insulin it 
was obvious that the nearly cubic crystals of the raw material were no more detectable after 
micronization. The micronization process resulted in very small and sometimes rounded 
fragments. The rounded shape of the jet milled particles is the typical particle morphology 
after jet milling and is assigned to attrition of the particles on each other or the walls of the 
mill [83,150]. This also explains the increasing incidence of these rounded particles with 
higher number of milling cycles. There is no difference in morphology between the samples 
ground without and with cooling. Obviously, the pictures confirm the particle size 
measurements by laser light diffraction. 
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Fig. 4.4 SEM pictures of insulin micronized under different conditions compared to the bulk material  
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Fig. 4.5 SEM pictures of lysozyme micronized under different conditions compared to the bulk 
material 
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Fig. 4.6 SEM pictures of BSA micronized under different conditions compared to the bulk material 
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Analysis of the results by DoE 
By using statistical analyses it was possible to fit a mathematical model based on equation 2.1 
to the data obtained from the particle size (d90 value) measurements after micronization. The 
factors milling pressure (x1), number of milling cycles (x2) and temperature of the milling gas 
(x3) were taken into account. It was obvious that higher milling pressure and higher number of 
milling cycles were decreasing the resulting d90 value for all three proteins, indicated by the 
negative coefficients. Differences were calculated for the significance of the other 
coefficients. Especially the impact of the milling gas temperature differed as mentioned 
before, which is reflected in the resulting equations, too. For insulin the temperature effect 
was not significantly different from zero and was therefore excluded from the model, but for 
lysozyme a small loss in milling efficiency was measured for the samples milled at 
temperatures about -60°C. The negative coefficient (x3) indicates that by raising the 
temperature from low to high level smaller particle sizes are obtained. In contrast to these 
results lower temperatures improved the milling efficiency for the jet milling of BSA. It is 
noticeable that for insulin a quite simple model was obtained with only two significant 
factors, one quadratic coefficient and no interactions between the three factors could be 
detected and therefore were excluded from the model. While for lysozyme all three factors 
had a significant impact and for BSA additionally all quadratic coefficients and even two 
interactions showed an effect on the d90 value.  
 
insulin: 
y=0.5879-0.0791x1-0.0643x2+0.0892x1
2
       (4.1) 
lysozyme: 
y=0.7681-0.0649x1-0.0793x2-0.0537x3+0.0228x2
2
      (4.2) 
BSA: 
y=1.1160-0.1038x1-0.1119x2+0.0217x3+0.0504x1
2
+0.0399x2
2
-0.2698x3
2
+0.0417x1x2-0.0941x1x3 (4.3) 
 
 
The 3D surface response diagrams, visualizing these results and the impact of the different 
parameters on the d90 value, are shown in figures 4.7 – 4.11. The different impact of the 
milling gas temperature on the resulting particle size of lysozyme and BSA is clearly visible. 
For insulin temperature was excluded as an insignificant factor. Therefore, it was possible to 
display the calculated results according to equation 4.1 in only one diagram. The mentioned 
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grinding limit is visible by the decreasing slope of the diagrams with higher pressure and 
higher number of milling cycles.  
The quality of the fit of the models is described by R
2
, the fraction of the variation of the 
response explained by the model, and Q
2
, the fraction of the variation of the response that can 
be predicted by the model. Therefore, R
2
 is an overestimated measure, and Q
2
 is an 
underestimated measure of the goodness of fit of the model. Large Q
2
, 0.7 or larger, indicates 
that the model has good predictive ability and will have small prediction errors [141]. The 
model fitted for insulin resulted in R
2 
= 0.893 and Q
2
 = 0.821, for lysozyme in R
2 
= 0.945 and 
Q
2
 = 0.903 and for BSA R
2
 = 0.959 and Q
2
 = 0.909 were calculated. These are very good 
parameters for the calculated models, which allows the prediction of particle sizes with new 
parameter combinations within the investigated range. These results also confirm that the 
selection of the investigated milling parameters included in the experimental setup was 
reasonable. As most material properties like hardness, brittleness and number and size of 
initial flaws, which are mentioned in chapter 1, are not known and hard to determine, it was 
not possible to correlate the differences of the equations of the calculated models to any 
material properties. Therefore, further experiments with new proteins are necessary. 
 
 
 
Fig. 4.7 Surface response diagram of insulin (d90 value) 
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Fig. 4.8 Surface response diagram of lysozyme (d90 value) at room temperature 
 
 
Fig. 4.9 Surface response diagram of lysozyme (d90 value) at cryogenic conditions 
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Fig. 4.10 Surface response diagram of BSA (d90 value) at room temperature 
 
 
Fig. 4.11 Surface response diagram of BSA (d90 value) at cryogenic conditions 
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Changes in particle size during storage 
A problem of some milled products is that during storage particle growth due to the activated 
surfaces of the particles appears [151]. The comparison of the particle sizes of the freshly 
milled samples with the results of the same sample after 4 weeks of storage at -20°C verified 
that the particles are stable during storage. Figure 4.12. shows the results for the micronized 
BSA powder samples. No particle growth or aggregation could be detected after measuring 
the particles by laser light diffraction. 
 
 
Fig.4.12 d90 value of micronized BSA directly after jet milling and after 4 weeks of storage 
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Summary 
For all three proteins jet milling proved to be a powerful tool for size reduction. The yield of 
about 80% per milling cycle is very good taking the very small amount of milled substance 
into account. In most cases particle size distributions with a d90 value below 10 µm were 
achieved. Based on the resulting size distribution curves the particle size of the bulk material 
was identified as one factor having a significant effect on the resulting distribution. By 
applying statistical experimental design it was possible to describe the impact of the different 
factors qualitatively and quantitatively. The occurring differences between the tested proteins 
could not completely be explained, but were a good indicator for the complexity of the 
process. Nevertheless, the chosen factors milling pressure, number of milling cycles and 
milling gas temperature proved to be the most important factors of the process, because being 
indicated by the R
2
 and Q
2
 values, which are close to 1, nearly all effects could be described 
by these parameters. Finally, the storage stability of the micronized protein powders was 
demonstrated, which is an important factor for using these powders as drugs. 
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Introduction 
Insulin is one of the most important and best investigated proteins and can be called in many 
ways the prototypic biopharmaceutical [152]. Its success is based on different factors, it was 
quite easily available in good purity even before recombinant protein production had been 
developed and on the other side the epidemiology of diabetes mellitus itself. The WHO 
estimates that in 2030 more than 350 million people will be suffering from diabetes, which 
makes insulin research an urgent and financially promising topic. Therefore many research 
groups are working on the processing and delivery of insulin [92,153,154]. Insulin is so far 
the only protein administered in crystalline form and was the first biopharmaceutical 
approved for delivery by the pulmonary route [13]. Therefore, insulin is the optimal 
therapeutic protein for testing the suitability of jet milling for the micronization of proteins. 
Insulin is an anabolic hormone with an important role in glucose and fat metabolism. The 
bovine insulin used for our experiments consists of 51 amino acids organized in two peptide 
chains A and B. Interchain disulfide bonds are located between the cysteines at positions A7 
and B7 and between positions A20 and B19. An intrachain disulfide bond occurs between the 
cysteines at A6 and A11. Bovine insulin differs from human insulin at the following 
positions: alanine for threonine at A8, valine for isoleucine at A10, and alanine for threonine 
at the carboxyl terminal of the B-chain [155]. For bioactivity testings a chondrocyte cell assay 
is available [123]. 
 
 
  
 Impact of Jet Milling on Insulin Chapter 5 
73 
Results and discussion 
Chemical stability of insulin 
First the impact of the jet milling process on the chemical stability of bovine insulin was 
investigated. HPLC experiments were performed to detect occurring degradation products. 
Figure 5.1 shows the results of these experiments. 
 
 
Fig. 5.1 RP-HPLC chromatogram of insulin at a detector wavelength of 210 nm 
 
No differences between the unprocessed control and the samples micronized sample could be 
detected. For all samples a main peak at 17.4 min and a small side peak appeared (retention 
time 18.1 min). The main peak was assigned to insulin and the small peak was identified as 
desamidoinsulin in an earlier study by Maschke et al. [92]. The ratio between these two peaks 
did not change comparing the unprocessed bulk material with the samples jet milled once at 
6 bar or three times at 14 bar. Similar results were found for the analysis of the samples by 
MALDI-ToF (fig. 5.2). The spectra of the bulk material and powder three times micronized at 
14 bar showed no significant differences. The main peak was at a molecular mass of 
5736.0 Da for the unprocessed material and at 4735.8 Da for the micronized sample. 
Overall the chemical stability of bovine insulin did not seem to be influenced by the 
micronization process in a jet mill. 
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Fig. 5.2 MALDI-ToF spectra of insulin  
 
Impact on secondary and tertiary structure  
The influence of the milling process on the structure of insulin in solution was analyzed by 
fluorescence methods and CD spectroscopy. 
Analysis of insulin solutions by CD spectroscopy revealed that only insignificant differences 
between the tested micronized and unprocessed samples were detectable (fig. 5.3). 
 
 
Fig. 5.3 CD spectra of insulin before and after micronization 
 
Intrinsic fluorescence measurements at an excitation wavelength of 280 nm resulted for all 
samples in emission maximum at 308 nm. As shown in fig. 5.4 small differences in the 
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maximum intensity were detected. Tyrosin fluorescence intensity dropped from 522 for the 
control to 487 for the samples micronized three times at 14 bar. Normally the two tyrosins in 
position A14 and A19 produce no fluorescence, because they are buried in the hydrophobic 
core and H-bonded to carbonyls [156]. Therefore, changes in the environment of the tyrosin 
residues in positions B16 and B26 have to be responsible for the reduced intensity after 
micronization. This effect can be caused by carbonyls or disulfide bonds which changed their 
relative position to these residues. 
 
Fig. 5.4 intrinsic fluorescence of insulin at 308 nm upon excitation at 280 nm (p<0.05) 
 
For further investigations the relative surface hydrophobicity of the protein in solution was 
analyzed by addition of a fluorescent probe (ANS). Again small differences were detected. 
The surface hydrophobicity of the sample micronized three times at 14 bar increased by 12 % 
compared to the unprocessed bulk material (fig 5.5). 
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Fig. 5.5 relative surface hydrophobicity (RSH) of insulin measured after addition of fluorescent probe 
ANS. 
 
All three methods revealed small differences in the secondary and tertiary structure of insulin. 
An important question is now, if these small differences have an effect on the bioactivity of 
the bovine insulin. 
 
Bioactivity assay for insulin 
Maintaining the bioactivity is the most important parameter while processing proteins. The 
bioactivity of insulin was tested by using a bovine chondrocyte cell assay utilizing the effect 
on cell proliferation and production of extracellular matrix. As illustrated in fig. 5.6 after 5 
weeks of cultivation no differences in cell number of the groups supplied with the micronized 
insulin compared to the groups with unprocessed insulin were visible. Pressure, milling cycles 
and temperature of the milling gas had no effect on the bioactivity of the bovine insulin. 
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Fig. 5.6 cell number of chondrocytes after 5 weeks of cultivation after having added different samples 
of insulin at two concentrations 
 
Additionally, histological cross sections of the chondrocyte containing fibrin gels were 
stained with safranin-O in order to visualize the glycosaminoglycans (GAG), an important 
compound of the extracellular matrix. As shown in fig. 5.7 the intensity of the red staining is 
much higher in the insulin containing groups. But no difference between unprocessed and 
micronized insulin supplied groups was visible, which supports the results of the cell number 
analysis. 
 
 
Fig. 5.7 Histological cross-sections after 5 weeks of cultivation, stained red for glycosaminoglycans 
(GAG) with safranin-O. a) Without insulin (control), b) with unprocessed insulin 2.5 µg/ml and c) 
with insulin micronized 3 times at 14 bar 2.5 µg/ml. 
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Summary and conclusion 
The micronization process seems to have only a small impact on the crystalline insulin. 
Analysis by HPLC and MALDI-ToF revealed no changes in the chemical structure and 
stability of the insulin molecules. Small changes were detected by fluorescence analysis. The 
intrinsic fluorescence was reduced and the relative surface hydrophobicity (RSH) increased, 
indicating small alterations in the tertiary structure of insulin. Nevertheless, these changes had 
no influence on the bioactivity of insulin tested in a chondrocyte cell assay. Nevertheless, 
regarding the sensitivity of the cell culture assay, which is lower than e.g. for an enzymatic 
assay, an impact of jet milling on insulin bioactivity cannot totally be excluded. 
Overall, the jet milling process seems to be a suitable method for the micronization of insulin 
and is a promising approach for the preparation of micron sized protein particles. 
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Introduction 
Lysozyme is an often used model in protein research [5,157,158]. Its properties and structure 
are very well investigated, because since the 1960s it has been in the focus of protein research 
[159–161]. Additionally its bioactivity is easyly accessible by measuring the lysis of 
micrococcus luteus cells turbidimetrically [125]. Therefore, lysozyme was chosen as a model 
substance for our jet milling experiments. 
Lysozymes are a group of enzymes defined as 1,4-β-N-acetylmuramidases cleaving the 
glycosidic bond between the C-1 of N-acetylmuramic acid and the C-4 of N-acetyl-
glucosamine in the bacterial peptidoglycan [161]. They are found in many tissues and 
secretions of vertebrates, invertebrates as well as bacteria, phages and plants. In the human 
body the highest concentration can be found within the tear fluid. As the main function a basic 
defense against infections is assumed. 
Chicken egg white lysozyme is a single chain polypeptide of 129 amino acids cross-linked 
with four disulfide bridges, containing 3 tyrosine, 6 tryptophan and 2 methionine [162] 
resulting in a molecular weight of 14307 Da.  
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Results and discussion 
Chemical stability of lysozyme 
The impact of the micronization process on lysozyme in solid state on the formation of 
degradation products was investigated by HPLC and MALDI-ToF analysis. 
The analysis of lysozyme by HPLC revealed no differences of the micronized samples to the 
unprocessed substance (fig. 6.1). No other peaks beside the main peak at 20.9 min were 
detectable for each sample. 
 
 
Fig. 6.1 HPLC chromatogram of lysozyme at a detector wavelength of 210 nm 
Also the mass analysis by MALDI-ToF showed no significant differences between the 
samples (fig. 6.2). The main peak at 7145.5 Da and 7156.0 Da respectively are due to double 
charged molecules and the peaks at 14304.0 Da and 14304.0 Da are due to the single charged 
molecules. For the sample micronized three times at 14 bar no additional peaks compared to 
the reference were detectable. 
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Fig. 6.2 MALDI-ToF spectra of lysozyme; lower spectrum in red shows results for the unprocessed 
bulk material, upper spectrum in blue the results after jet milling three times at 14 bar 
 
Impact on secondary and tertiary structure 
The effect of the jet milling process on the secondary structure of lysozyme in solution was 
investigated by CD measurements and subsequent analysis of the structure composition by 
applying the CDNN algorithm. 
The results for lysozyme shown in fig. 6.3 demonstrate that no significant changes in the 
secondary structure in solution could be detected. Consequently no differences in the analysis 
of the structure composition by using CDNN algorithm were determined (fig 6.4). 
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Fig. 6.3 CD spectra of lysozyme (control, 1x14bar, 2x14bar, 3x14bar) 
 
 
control  1x14 bar  2x14 bar  3x14 bar  
Helix 21.0%±1.68  21.4%±2.38  21.1%±2.44  20.9%±2.25  
Antiparallel 19.7%±1.52  18.6%±1.73  19.1%±2.06  19.5%±1.98  
Parallel 5.5%±0.10  5.5%±0.05  5.4%±0.06  5.5%±0.05  
Beta-Turn 18.4%±0.29  18.1%±0.33  18.3%±0.37  18.3±0.33  
Random Coil  33.1%±1.11  33.1%±2.01  30.4%±6.29  33.0%±1.65  
Fig. 6.4 Results of secondary structure composition analysis by CDNN algorithm 
 
Similar to insulin lysozyme was analyzed by two different fluorescence methods for changes 
in tertiary structure. The intrinsic fluorescence measurements were performed at a wavelength 
of 295 nm for the excitation of the 6 tryptophan residues. The maximum of the tryptophan 
fluorescence was at about 394.5 nm for all samples and depending on the number of milling 
cycles the intensity was reduced from 200 for the control to 175 measured for the sample 
milled three times at 14 bar (fig. 6.5). Possible reasons for a reduction of tryptophan 
fluorescence are that the residues are now in a more hydrophobic environment, quenched by 
disulfide bonds or a greater distance to tyrosin residues, which can intensify tryptophane 
fluorescence via nonradiative energy transfer, if the distance between them is smaller than 10-
18Ǻ [163]. 
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Fig. 6.5 Intrinsic fluorescence of lysozyme at an excitation wavelength of 295 nm (p<0.05) 
 
After having added ANS as a hydrophobic probe the relative surface hydrophobicity of the 
protein in solution was determined. A 12-fold increase of relative surface hydrophobicity 
indicates dramatic changes in the tertiary structure of lysozyme (fig. 6.6). Nevertheless, by 
comparing the secondary structure of the reconstituted micronized proteins with that of the 
native proteins in solution measured by circular dichroism spectroscopy no significant 
changes were visible. This observation of an increasing surface hydrophobicity without 
changes in secondary structure of lysozyme was already described by Lechevalier et al. [129]. 
 
Fig. 6.6 Relative surface hydrophobicity (RSH) of lysozyme in solution with ANS as hydrophobic 
probe (p<0.05) 
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Bioactivity assay for lysozyme 
For the analysis of the bioactivity of lysozyme all samples were tested using the micrococcus 
assay. Examination of the results showed that at the harshest conditions lysozyme activity 
decreased to 88 % compared to the unprocessed sample. Analyzing the results for the 
influence of the milling parameters it became clear that temperature of the milling gas had no 
significant effect on the resulting bioactivity. The decrease depended significantly on the 
chosen milling pressure and number of milling cycles. It was possible to fit a model 
describing the obtained data (R
2 
= 0.776, Q
2 
= 0.706). Figure 6.7 illustrates the impact of 
milling cycles (x2) and of the used pressure (x1). Performing the experiments in presence of 
1mM Detapac for complexation of iron ions had no effect on measured bioactivity. 
 
 
Fig. 6.7 Activity of lysozyme in percent depending on number of milling cycles and milling pressure. 
Both factors decrease activity of lysozyme, but the number of milling cycles has a bigger effect 
(𝑦 = 92.0864 − 1.3292x1 − 3.0048x2) 
 
Based on the equation in fig. 6.7 you can state that the number of milling cycles had a bigger 
impact on the activity of lysozyme than the applied pressure. In literature the negative effect 
of acceleration in a jet stream and following impaction on bioactivity of catalase particles is 
described [17]. When comparing the bioactivity results of insulin and lysozyme it is important 
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to keep in mind that the sensitivity of the enzymatic assay of lysozyme is much higher than 
for the chondrocyte cell assay of insulin. Nevertheless, for insulin the mechanical stress in the 
jet mill seemed not to influence its bioactivity. One reason for these different results could be 
the much larger lysozyme particles in the beginning. Due to this fact particles had to undergo 
many more breakage events to reach the same sizes as determined for insulin. During 
breakage events temperatures of several hundred Kelvin may occur at the newly created 
surfaces [107], which may lead to persisting changes in the molecules at the particle surface. 
 
Determination of the iron content 
Another factor which may decrease the bioactivity of lysozyme and cause a drop in 
fluorescence intensity is metal wear of the mill components. The iron content was measured 
for selected lysozyme samples by ICP-OES. A slight increase depending on the number of 
milling cycles was detected (fig. 6.8). The content of the unprocessed control sample was 
6.32 ppm, which increased to 8.9 ppm after three cycles at 14bar. 
 
 
Fig. 6.8 Iron content of lysozyme powder determined by ICP-OES measurements (p<0.05) 
 
Platz et al. described that after micronization of human growth hormone 40 % of the powder 
was insoluble in water [81]. It was possible to reduce this fraction to 2.5 to 7.5 % by 
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exchanging some silver soldered joints and copper gas lines with more inert materials like 
stainless steel. However, with the used setup for these experiments only stainless steel and 
PTFE came in contact with the proteins. An effect of iron, which is the essential element in 
stainless steel, on lysozyme was described by Sellak et al. [164]. It was published that 
lysozyme is able to bind iron and is then much more sensitive to damages by radicals which 
results in a loss of bioactivity. Additionally, a decrease in tryptophan fluorescence was 
described. However, these results were described for concentrations higher than 1800 ppm 
and our results showed only a small increase from 6 to 9 ppm of iron content within the 
milled powder, which is probably due to attrition in the milling chamber. As mentioned 
before the addition of an iron complexing agent (Detapac) to the tested protein solutions did 
not show any improvement in lysozyme bioactivity. Therefore, a reduction of the bioactivity 
of lysozyme by metal contamination due to attrition can be neglected. 
 
Impact of jet milling on lysozyme crystals 
Another interesting question was, if the solid state itself has an effect on the protein stability. 
As described before, no loss in activity was determined for the crystalline insulin but for the 
freeze dried lysozyme. Therefore, the impact of the jet milling process on lysozyme crystals 
was tested, too. 
The crystals, obtained by a method described in chapter 2, showed a broad size distribution 
between 1 and 1000 µm with a d90 value of 85.6 µm (fig. 6.9). After one cycle at 14 bar the 
d90 was reduced to 6.9 µm with some coarser particles still present. Three cycles at 14 bar 
resulted in narrow distribution with a d90-value of 4.3 µm, which is slightly smaller than for 
the freeze dried powder. 
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Fig. 6.9 Size distribution of lysozyme crystals before and after micronization 
 
The bioactivity experiments revealed that even for the lysozyme crystals a drop in activity 
was present. Similar to the previous results the activity was reduced to 89 % after three 
milling cycles at 14 bar (fig. 6.10). For lysozyme the crystalline form seemed not to increase 
the stability against changes due to the mechanical stressing by the milling process. 
 
Fig. 6.10 Bioactivity of crystalline lysozyme before and after micronization 
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Summary and conclusion 
The experiments with lysozyme revealed that the chemical stability was not influenced by the 
micronization process. By HPLC and MALDI-ToF no changes due to the milling process 
were determined. Also no significant differences in the secondary structure analyzed by CD 
spectroscopy were visible. However, by fluorescence measurements significant differences 
between bulk material and the micronized powder were detected indicating changes in the 
tertiary structure of the protein. The intrinsic fluorescence due to tryptophane decreased by 
about 12% and the surface hydrophobicity (RSH) in solution increased 12-fold compared to 
the reference. These changes seemed to be the reason for the drop in activity determined after 
micronization. Higher iron content due to attrition in the milling chamber was excluded as a 
reason for this decrease. This effect was not influenced by the solid state of lysozyme. The 
investigated crystals showed similar results as the freeze dried form. 
As a conclusion it can be stated that there are structural changes within the protein molecules 
induced by the jet milling process resulting in a decrease in bioactivity. As the most critical 
parameter seems to be the number of milling cycles, repeated milling should be avoided. 
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Introduction 
As third model protein for the micronization experiments BSA was chosen. It is a well-
studied protein often used as a model substance for example in controlled release experiments 
[165] or as reference and calibration substance in several methods for protein analytics, like in 
the bicinchonic acid assay for protein quantitation [126] or utilized to prevent protein 
adsorption to surfaces. As the most abundant plasma protein it is easily available in larger 
amounts by isolation from bovine plasma. BSA has a single polypeptide chain consisting of 
about 583 amino acid residues (66 430 Da [166]) building up three domains each stabilized by 
a network of in all 17 disulfide bonds  and one free thiol group [167]. In-vivo it plays an 
important role in colloidal osmotic blood pressure and is responsible for the transport, 
distribution and metabolism of a variety of substances to which it binds (metals, fatty acids, 
hormones and therapeutic drugs) [168].  
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Results and discussion 
Impact of jet milling on the solubility of BSA 
While preparing the micronized BSA samples for analysis it occurred that it was not possible 
to completely dissolve the micronized sample in water. In order to investigate if this 
phenomenon is linked to some milling parameters, the amount of the insoluble fraction was 
determined. Fig. 7.1 shows the results for the different samples. 
 
 
Fig. 7.1 influence of milling pressure (6 to 14 bar), number of milling cycles (1 to 3) and milling gas 
temperature on the amount of insoluble BSA fractions 
 
A correlation between the milling parameters pressure, number of milling cycles and milling 
gas temperature is with the incidence and amount of insoluble fractions is clearly visible. For 
the samples ground at room temperature with increasing pressure and increasing number of 
milling cycles the amount of insoluble BSA increased significantly. Starting from 3.9 % for 
one cycle at 6 bar leading to a maximum of 13.9 % at 2 cycles at 14 bar. At 14 bar no further 
increase due to the milling cycles was detectable, since the values reached a plateau. For the 
samples processed at cryogenic conditions the results were different. Nearly no impact of the 
milling gas pressure was visible and only a small effect of the milling cycles. The amount of 
the insoluble fraction stayed constant in a range of 6-9 %. For quantifying these effects the 
results were analyzed by statistical experimental design methods using the same setup as for 
the particle size analysis, but using the amount of the insoluble fraction in percent as the 
response parameter. 
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A model with a Q
2
 value (the fraction of the variation of the response that can be predicted by 
the model) of 0.923 and a R
2
 value (the fraction of the variation of the response explained by 
the model) of 0.972, which are both indicating an excellent fitted model. The calculations 
resulted in the following equation: 
 
y=7.1230+2.1300x1+1.2549x2+1.3323x3+1.7027x1
2
-0.4677x1x2+1.5983x1x3 
 
The highest factor for x1 indicates that the applied milling pressure had the biggest impact on 
the creation of insoluble BSA fractions. Also the effect of the temperature is confirmed. This 
is a hint that the process leading to the insoluble fractions is partly temperature dependent and 
may be due to the created heat at the breakage surfaces of the protein particles [107]. 
Based on these results two questions occurred. First: what changes in the solid BSA powder 
are induced by the milling process and second: is it possible to prevent the creation of 
insoluble fractions? 
 
SEM pictures of the remainder 
The SEM pictures of the insoluble fraction gave no hint about the underlying mechanism. As 
shown in fig.7.2 only an unstructured mass was visible, due to agglomeration and the 
centrifugation steps. 
 
 
Fig. 7.2 SEM picture of the remainder after dissolving micronized BSA in water 
 
10 µm
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Dissolution tests with the water insoluble BSA fractions 
To identify the changes within the BSA several solvents were tested in order to get the 
remainder into solution. The results showed that the water-insoluble BSA fraction was 
dissolved only by a combination of denaturizing and reducing agents. 6M urea or 6M 
guanidine HCl both in combination with 10mM dithioerythritol and 1mM EDTA were the 
only suitable solvents. For all other setups only the appearance of the sediment differed. In 
hydrophilic environment like water big flakes formed and in more lipophilic media the 
powder particles stayed separated. This indicates that the insoluble particles had a more 
lipophilic surface and wettability may be part of the problem. Nevertheless, only the 
combination with a reducing agent like dithioerythritol resulted in a clear solution. The fact 
that dithioerythritol alone was not able to dissolve the protein aggregates implied that the 
wettability of the particles by this solution was too low or that not all the disulfide bonds were 
accessible and only the combination with the denaturizing agents loosened the aggregates. 
Therefore, chemical reactions like a disulfide interchange were possible explanations for the 
creation of insoluble fractions. Similar results are known for the moisture-induced 
aggregation of BSA Liu et al. [169]. 
Nevertheless, the found solvents were not suitable for performing further analysis, because 
the molecule structure had been totally destroyed und all disulfide bonds had been broken up 
so that no differences between the samples were detectable. Therefore, further experiments 
were needed to investigate if sulfhydryl groups are responsible for the creation of the 
insoluble fraction. 
 
Determination and blocking of free SH-groups 
BSA contains 17 disulfide bonds and one free thiol group of a cysteine residue. This 
facilitates the possibility of a thiol-disulfide interchange by a nucleophilic attack of an ionized 
thiol on a disulfide linkage resulting in covalent protein aggregates. Therefore, the idea was to 
block the free thiol groups and investigate the effect on the solubility properties after 
micronization. 
As described in chapter 2 the determination of free thiol groups was performed by using 
Ellman´s reagent. Fig. 7.3 shows the free thiol groups per molecule BSA before and after S-
alkylation by iodoacetamide determined by this method. BSA provides 0.4 free SH-groups 
per molecule, which matches the values described in literature [165]. The fraction without a 
free sulfhydryl group is due to interaction with plasma cysteine and a less content with 
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glutathion [170,171]. By S-alkylation the content was reduced to 0.05 free SH-groups per 
molecule. 
 
 
 
Fig. 7.3 SH-groups per molecule BSA. Left bar shows results for unprocessed BSA, middle bar shows 
effect of S-alkylation by iodoacetamide, right bar shows impact of the preparation process for S-
alkylation without addition of iodoacetamide. 
 
This modified BSA was now micronized at 14 bar one to three times. The unmodified BSA 
was micronized, too, because a new batch of BSA was used for these experiments. The 
following analysis of solubility in water showed that no significant difference between the 
samples was obtained (fig. 7.4). The slightly lower values compared to Fig. 7.1 are due to the 
used new batch of BSA despite the fact that for the old batch only 0.15 free thiols per 
molecule BSA were measured. 
Therefore, the impact of the free SH-group on the creation of insoluble fractions by thiol 
disulfide interchange can be neglected. 
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Fig. 7.4 comparison of the amount of insoluble BSA before and after S-alkylation micronized 
at 14 bar one to three times; left three bars show the results of SH-blocked BSA, as a 
comparison right three bars show results for unmodified BSA 
 
HPLC analysis of soluble BSA fraction 
The solution was also analyzed by HPLC. The comparison of the different samples revealed 
no changes for the SH-blocked samples. Nevertheless, a small difference was detected for 
unmodified BSA. A small peak visible in the unprocessed sample (retention time 15.3 min), 
not completely separated from the main peak (retention time 13.9 min), disappeared in the 
micronized sample (Fig. 7.5). Unfortunately it was not possible to increase the resolution or 
relate the peak to a specific substance. 
 
 
Fig. 7.5 HPLC analysis of different BSA samples at 210 nm 
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Micronization of l-glutathione (GSH) 
In order to investigate if oxidative processes involving the free SH-group are responsible for 
the formation of intermolecular disulfide bonds, micronization experiments were performed 
with l-glutathione, a small and easy to analyze peptide with a free SH-group. For such a small 
peptide the probability of reactions should be increased and the formed aggregates should be 
soluble in water and therefore accessible to analytical methods. 
The reduced form of GSH containing the free SH-group was micronized 3 times at 14 bar and 
afterwards was analyzed for changes by using the thiol assay and HPLC. Fig. 7.5 shows the 
free SH-groups per molecule of the unprocessed bulk material (GSH red) compared to the 
reference of the oxidized form (GSH ox) and to the three times micronized sample of the 
reduced form. 
 
Fig. 7.5 Free thiol content per molecule GSH of the reduced (GSH red) and oxidized form (GSH ox) 
compared to the jet milled reduced form 
 
No changes after the jet milling process compared to the unprocessed reference were visible. 
These results were confirmed by the results of the HPLC analysis of these samples (fig. 7.6). 
For the reduced form, one main peak related to the monomer with the free thiol groups and a 
small peak identical to the oxidized form was detected. After micronization the same 
chromatogram was obtained with no additional peaks and no changes in the peak to peak 
ratio. 
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Fig. 7.6 HPLC chromatogram obtained at a detector wavelength of 210 nm of GSH in reduced and 
oxidized form and after jet milling three times at 14 bar 
 
These results support the results from the BSA experiments, indicating that the free thiol 
groups are not reactive under the conditions during the jet milling process and are not 
responsible for the creation of insoluble fractions of BSA and therefore an alkylation of the 
free SH-group did not improve the results of the BSA micronization. 
 
Micronization of fatty acid free BSA (BSA FAF) 
Based on the results of the solvent experiments, another reason for the formation of insoluble 
particles may be an increased hydrophobicity on the surface of the micronized protein 
particles. Normally up to 3 mol/mol fatty acids are bound to BSA [172]. These consist mainly 
of mono unsaturated or saturated C16 and C18 fatty acids. In solution bound fatty acids result 
in compact conformation of the BSA molecule [173] and diminish the accessibility of 
albumins disulfide bonds in aqueous solutions [174]. Costantino et al. stated that the removal 
of the fatty acids increased the solid state aggregation of BSA [165]. Therefore, experiments 
were performed with fatty acid free BSA (fatty acid content <0.01 %). 
Our experiments showed no significant difference (comparison of samples with the same 
number of milling cycles) of the fatty acid free samples to the fatty acid containing ones 
(fig. 7.7). Only a small trend to less insoluble fractions was visible, which is a contrast to the 
before mentioned literature results. 
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Fig. 7.7 Resulting insoluble fraction after micronization of fatty acid free BSA (BSA FAF) (bars 2, 3 
and 4) compared to the fatty acid containing standard BSA (bars 5, 6 and 7); first bar shows results of 
the control group with unprocessed fatty acid free BSA 
 
One possible reason may be a rearrangement of the fatty acids on the surface of the protein 
particles due to the micronization process increasing the surface hydrophobicity. 
 
Fluorescence measurements of BSA in solution 
Besides the insoluble fractions the characterization of the soluble fraction was important. The 
samples were analyzed for changes in the tertiary structure of BSA molecules by fluorescence 
methods. Intrinsic fluorescence measurements are a useful tool to identify structural changes 
within the tertiary structure of proteins, while the utilization of a hydrophobic probe like 8-
anilino-1-naphtalenesulfonic acid ammonium salt (ANS) reveals changes at the surface of the 
protein molecule. 
The intrinsic fluorescence measurements showed an emission maximum at 351 nm for all 
samples and the fluorescence intensity was equal for all samples (fig. 7.8). This indicates that 
no changes in the environment around the excited tryptophan residues were induced by the 
micronization process. 
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Fig. 7.8 intrinsic fluorescence intensity measured at a wavelength of 351 nm of BSA before and after 
micronization; first bar shows results of the unprocessed BSA in comparison to samples micronized at 
a pressure of 14 bar one to three times at room temperature (bars 2, 3 and 4) and at cryogenic 
conditions (bars 5, 6 and 7) 
 
The surface hydrophobicity of the BSA molecules in solution was investigated by addition of 
ANS as a hydrophobic probe. In a hydrophobic environment, e.g. by hydrophobic amino acids 
on the surface of the protein, the fluorescence intensity of ANS is increased. The calculated 
relative surface hydrophobicity (RSH) revealed a significant decrease of hydrophobicity for 
the micronized samples compared to the unprocessed bulk material (fig. 7.9). 
 
Fig. 7.9 Relative surface hydrophobicity (RSH) of BSA in solution; samples were jet milled at 14 bar 
one to three times at room temperature (bars 2, 3 and 4) and cryogenic conditions (bars 5, 6 and 7) 
compared to unprocessed BSA (left bar) 
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Between the samples jet milled at room temperature and these milled at cryogenic conditions 
no differences were visible. The observed decrease in surface hydrophobicity of the protein 
molecules in solution indicates a rearrangement of the surface structure presented to the water 
interface. Hydrophobic groups seem to be transferred to the interior of the molecules. 
Remarkably these changes had no effect on the intrinisic fluorescence measurements. 
 
FT-IR analysis of the BSA powder 
In order to get an idea of the structural changes within the protein powder due to the 
micronization process FT-IR experiments were performed with the samples in solid state. By 
FT-IR measurements it is possible to investigate the secondary structure of proteins in solid 
state. Because it was not possible to dissolve the insoluble fraction without destroying the 
whole molecule structure, FT-IR analysis seemed to be a good option to get a closer look on 
the obvious changes induced by the jet milling process to part of the BSA proteins. Tests were 
performed with samples micronized at 14 bar, which were compared with the unprocessed 
BSA powder. Additionally a sample of the separated insoluble fraction was analyzed. 
The evaluation of the second derivative analysis of the amide I region showed differences of 
the micronized samples to the reference (fig. 7.10). 
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Fig. 7.10 Comparison between the areas under the different peaks visible in the second derivative of 
the measured absorption at different wavenumbers by FT-IR 
 
Unexpectedly the isolated insoluble fraction showed no difference to the unprocessed BSA 
powder. The most probable reason is that the particle size of the samples had a significant 
effect on the measured result [193], because the sample of the insoluble fraction had been 
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obtained after centrifugation in water in order to separate it from the soluble fraction. The 
result was a flake-like structure. Although the samples were ground in an agate mortar before 
measurement no sizes below 10 µm were achieved like for the micronized samples. 
 
Co-lyophilization of BSA with poly(ethylene glycol) (PEG) 
So far three possible reasons for the formation of insoluble BSA fractions were discussed. 
First, the heat created during the milling process, indicated by the reduced amount of 
insoluble particles after jet milling under cryogenic conditions. Second, the formation of BSA 
aggregates and third, an increase of surface hydrophobicity of the particles. To inhibit these 
phenomenons the idea was to embed BSA into poly(ethylene glycol) (PEG) as a so-called 
bulking agent [175]. On the one side it would minimize the intermolecular contact between 
single BSA molecules and on the other side it could result in a hydrophilization of the 
resulting particles. To investigate the effect, BSA was mixed at different ratios with PEG 
10 000, dissolved in water and freeze-dried afterwards. The freeze-dried powder was 
micronized in the jet mill under the same conditions as the pure BSA samples. 
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Fig. 7.11 SEM micrographs of BSA PEG mixtures after freeze-drying and after micronization 
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Particle size analysis revealed that depending on the ratio of BSA and PEG the d90-value 
changed. The higher the PEG content was the larger were the resulting particle sizes 
(fig. 7.12). Fluctuations after one milling cycle are mostly due to differences in the particle 
size distribution of the starting material after freeze-drying.  
 
Fig. 7.12 Particle size (d90-value) after micronization at 14 bar for the different BSA PEG mixtures 
 
Afterwards the amount of the insoluble fraction for the different samples was analyzed. It 
appeared that with increasing PEG ratio this fraction was decreased and at a ratio BSA to 
PEG of 2:1 no insoluble particles were detectable anymore (fig. 7.13). 
 
Fig. 7.13 Determination of the insoluble fraction of the different BSA PEG mixtures after 
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This effect of PEG is probably due to the combination of the aforementioned effects of 
separating the BSA molecules and keeping the particles hydrophilic. Additionally the fact that 
with a higher amount of PEG more heat of the grinding process is transferred to PEG 
molecules than to BSA. That increased the protection of the BSA molecules furthermore. 
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Summary and conclusion 
Due to the micronization of BSA by jet milling insoluble fractions of protein powder were 
created. Depending on the milling parameters the amount of this fraction reached up to 14 %. 
Three possible reasons for this phenomenon were discussed and investigated. First, the 
influence of possible heat creation on the particle surface during the particle breakage was 
confirmed by the positive effect of cryogenic milling gas temperatures on the reduction of the 
insoluble fraction. Second, thiol group reactions were investigated. Based on the fact that the 
remainder was only soluble by the combination of denaturizing and reducing agents, a thiol 
disulfide interchange as described by literature [169] was probable. Nevertheless, blocking the 
crucial free thiol group did not improve the milling results. Experiments with l-glutathion 
revealed that no oxidation of SH-groups took place caused by the applied milling conditions. 
Third, an increased surface hydrophobicity was suggested, but fluorescence measurements in 
solution were contradictory to this assumption. Nevertheless, micronization of fatty acid free 
BSA improved the results slightly. 
No analytical method was found to characterize the insoluble fraction in detail. By dissolving 
the remainder with denaturizing and reducing agents the structure of the protein was totally 
destroyed and no hints for former changes were detectable. Unfortunately FT-IR 
measurements seemed to be influenced more by the particle size of the samples than by 
structural changes. 
Nevertheless, besides the lowering of the milling gas temperature the mixture of BSA with 
PEG as a bulking agent was successful in lowering the amount of the insoluble fraction. 
Additionally it facilitated another parameter for controlling the final particle size. 
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Introduction 
As mentioned in chapter 1, release systems which deliver proteins for several days or even 
months are investigated. They are one option of enhancing the compliance with protein drugs 
of the patients. Optimally, these devices are easily administrable and consist of a material that 
has an adjustable release profile, is biocompatible, biodegradable and does not harm but rather 
stabilizes the sensitive protein drugs. Several materials were tested during the last three 
decades, e.g. containing: (1) natural materials, like albumin, cellulose, chitosan, hyaluronic 
acid, dextran and starch; (2) synthetic polymers, like polyanhydrides, polyamides, polyesters 
and polyorthoesters; (3) hydrogels, consisting of alginates, collagen, fibrin or gelatine [176]; 
and (4) lipid materials, like cholesterol, fatty acids, lecithin, waxes, dipalmitoyl-
phospatidylcholin, mono- and triglycerides [177]. They were applied as nano- or 
microparticles, cylindrical implants or scaffolds for tissue engineering, which are just some of 
the tested formulations. 
Synthetic polymers like poly(lactid-co-glycolic acid) (PLGA) are most often used at the 
moment. They can be easily customized and have a defined structure and therefore well-
defined degradation pathways [178]. Their acceptable biocompatibility is well investigated 
[179,180] and many are approved by the FDA. Nevertheless, some drawbacks in combination 
with protein drugs occurred. During the preparation steps high shear forces, temperature 
increase and the use of organic solvents are often necessary [181] and proteins may be harmed 
by the occurring interfaces [182]. Additionally, during the erosion of the polymers the 
microenvironment within the devices often changes. A drop of the pH, an increase of the 
osmotic pressure and acylating degradation products [183] are fatal factors for protein 
stability and bioactivity. 
Lipid materials, like triglycerides, are one alternative group of materials for the development 
of controlled release drug delivery devices. They are generally recognized as biocompatible 
and biodegradable [184] due to the fact that they are substances physiologically found in the 
body. Several proteins, e.g. insulin [185], somatostatin [186], thymocartin [187], Interleukin-
18 [79] and BSA [188] have been incorporated in different lipid formulation, like compressed 
cylinders or microparticles resulting in protein release over days or even months. 
Triglycerides proved to be promising material for protein release without the induction of 
protein degradation. 
Nevertheless, the production of protein containing microparticle formulations tends to be a 
critical and difficult process. Especially formed interfaces and high shear forces during the 
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preparation step are very critical for protein stability. Solvent evaporation, melt dispersion 
techniques [189] or spray drying of O/W emulsions or of organic lipid solutions [190] are 
prone to harm proteins. So several excipients have to be added to maintain protein stability or 
increase encapsulation efficiency. Therefore, there are approaches to incorporate proteins into 
microparticles as solids. Maschke et al. encapsulated insulin into lipid microparticles with an 
average diameter of 230 µm by spray congealing of a protein suspension in molten lipid 
without any loss in protein integrity [185]. Nevertheless, structure modifications of the lipid 
were detected after this process due to the rapid freezing of the molten mass, which leads to 
recrystallization and structural change during storage and protein release. 
Due to these observations the idea of jet milling of lipids to obtain microparticles was born. 
Jet milling is a well known method for powder micronization and is often indicated for the 
processing of heat sensitive substances. However, high temperatures occurring on the 
breakage surface are possible [107]. When micronizing lipids some questions should be 
investigated: 
1. Is it possible to micronize lipids, as very soft substances, by jet milling and establishing it 
as an alternative method for lipid microparticle preparation? 
2. How are the particle properties influenced by the milling process? Are there changes in 
structure or modification of the investigated lipid? 
3. Is it possible to correlate these changes to process parameters of the milling process, like 
milling gas temperature, and may lipids be utilized as model substances to analyze 
energetic effects of jet mill grinding on products? 
Some experiments were performed to get a basic understanding of the underlying processes. 
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Results and Discussion 
Particle size and size distribution 
The sieved glycerol tripalmitate was micronized at 4 bar at room temperature and under 
cryogenic conditions with a milling gas temperature of -65°C. Measurements by laser light 
diffraction revealed that after one milling cycle particles with a d50 value of 34.5 µm at room 
temperature and 24.5 µm after cryogenic grinding were obtained (fig. 8.1 and 8.2 upper 
graphics). However, the size distribution was very broad with particles up to 1000 µm 
indicating a large fraction of non-milled particles. The result was improved by repeated 
stressing of the lipid powder. After 3 milling cycles narrow size distributions with an average 
diameter of 9.7 µm at room temperature and 8.3 µm for the cryomilling experiments were 
determined. For both setups the d90 value was below 20 µm after the three milling cycles.  
These results clearly show that for glycerol tripalmitate one milling cycle did not lead to a 
sufficient particle size reduction. Glycerol tripalmitate is quite a soft material which tends to 
deform plastically without initiating cracks due to mechanical stressing. Repeated stressing 
may induce an embrittlement of the substance and enhance the size reduction process [101]. 
Another factor influencing the resulting particle size was the milling gas temperature. 
Especially after the first milling cycle the difference was obvious, with d50 values discerning 
by 10 µm. The relatively low melting point of glycerol tripalmitate (onset 62.71°C, maximum 
64.79°C) may be one reason why it tended to deform more plastically due to impact grinding 
at room temperature than at a milling gas temperature of -65°C. This effect is exploited for 
the cryogenic grinding of some rubber-like materials [136]. 
Particle size measurements were repeated after three weeks of storage at room temperature 
and compared to the aforementioned results, which were measured on the day of production. 
An increase of particle size was determined for all samples (fig. 8.1 and 8.2 lower graphs). 
The d50 values of the samples ground at room temperature increased from 34.5 µm up to 
146.6 µm (1x4 bar) and from 9.6 µm to 13.6 µm (3x4 bar), respectively. Particle size of the 
cryomilled samples increased as well, from 24.5 µm to 30.7 µm and from 8.3 µm to 9.9 µm. 
Jet milling seems to induce changes within the lipid particles which result in particle growth 
during storage of the samples. These changes may be caused by high temperatures occurring 
at the breakage surfaces as described by Weichert et al. [107]. Glycerol tripalmitate is a highly 
crystalline substance normally existing in the stable β-modification. The applied stress and 
increased temperatures could probably result in an amorphisation of the particle surfaces or 
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even in the formation of polymorphic structures. For glycerol tripalmitate an unstable α-
modification and a metastable β´-modification are described [191,192]. 
 
 
 
 
Fig. 8.1 Particle size distribution of lipid microparticles after jet milling at room temperature and 4 
bar compared to the results after 3 weeks of storage 
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Fig. 8.2 Particle size distribution of lipid microparticles after jet milling under cryogenic conditions at 
4 bar compared to the results after 3 weeks of storage 
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Particle morphology 
First scanning electron microscopy was applied to see if the increase in particle size is visible 
by this method, too, and if it is possible to determine the reason for this particle growth. 
Figures 8.3 and 8.4 show glycerol tripalmitate particles directly after micronization and after 
three weeks of storage at room temperature, each in two different magnifications. For 
comparison reasons the starting material is visible in the first line. 
The size reduction effect of jet milling on the lipid particles is clearly recognizable. The 
freshly ground material displays small particles without sharp edges and with a smooth 
surface. For the samples milled only once some larger particles were detectable. There were 
no obvious differences in morphology between the two different milling gas temperatures. 
After three weeks of storage a tremendous change in surface structure appeared. It changed to 
very rough and spiky structures, which indicates a crystallization process on the surface of the 
particles [185]. The SEM pictures of the three weeks old samples give an impressive insight 
into the events responsible for particle growth. Particles were highly agglomerated and 
interconnected due to the grown spikes on the surface. When having a closer look, the 
changes on the cryomilled particles seemed to be less prominent and the spikes were smaller. 
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Fig. 8.3 SEM picture of glycerol tripalmitate milled at room temperature and 4 bar directly after 
micronization and after 3 weeks of storage at room temperature 
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Fig. 8.4 SEM picture of glycerol tripalmitate milled at cryogenic conditions and 4 bar directly after 
micronization and after 3 weeks of storage at room temperature 
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Thermal behavior of micronized lipid particles 
Thermal analysis is the standard method for investigating lipids. Therefore, DSC 
measurements were applied to verify the visible changes within the particle structure and to 
detect probable differences between the samples. Figure 8.5 shows the thermogram of the 
glycerol tripalmitate bulk material showing one endothermal event with an onset at 62.71°C 
and a maximum at 64.79°C, which are typical values for the melting point of this material. 
The micronized samples were analyzed by DSC at the same time points as investigated with 
the other methods before. For comparison figures 8.6 and 8.7 show thermograms zoomed in 
on the area of interest. 
Each freshly micronized sample showed an exothermal event in the area between 35 and 
50°C. A dependence of the number of milling cycles is clearly visible as with each additional 
milling cycle the exothermal event increased. This effect was reduced by applying the cooled 
milling gas for the milling process. The detected differences were less prominent, indicating 
that alteration of the surface is due to heat generated during the milling process. After three 
weeks still some differences were detectable for the room temperature milled samples, but the 
curves were much closer to the ―baseline‖ of the bulk material. After three weeks the 
cryomilled samples were not any more distinguishable from the bulk material. The energy 
input by heat due to particle breakage induces the creation of unordered structures on the 
particle surfaces. During storage these activated structures return to the low energy and stable 
crystalline state by recrystallization, an exothermic process. 
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Fig. 8.5 DSC melting curve of glycerol tripalmitate bulk material 
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Fig. 8.6 Comparison of micronized lipid processed at different temperatures, analyzed by DSC 
directly after production 
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Fig. 8.7 Comparison of micronized dynasan 116 processed at different temperatures and stored for 3 
weeks at room temperature, analyzed by DSC 
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Summary 
The experiments demonstrated that it is possible to obtain microparticles of glycerol 
tripalmitate as an example for lipid materials by jet milling. However, only repetitive milling 
resulted in a narrow size distribution with most particles below 20 µm. Cryomilling improves 
the result significantly. By utilizing lipids as milling samples it was possible to prove surface 
activation effects due to the jet milling process. As demonstrated in chapter 3 this process is 
not initiated by a heating up of the milling gas, but the changes are caused by heat created by 
the impact itself and by the heat occurring during the crack propagation of particle breakage 
[107]. This effect can be influenced by reducing the temperature of the milling gas, but cannot 
be totally prevented. Unstructured areas with a higher energy level were created on the 
particle surface leading to recrystallization processes on the surface of the lipid particles, 
which resulted in particle growth during storage. 
Jet milling is often indicated for the micronization of heat sensitive substances due to the 
cooling effect of the expanding gas stream. Nevertheless, the energy induced by the high 
velocity impacts and particle breakage may result in alterations of the substance. This effect 
may be also responsible for the observations made for protein grinding described in the 
previous chapters. 
Lipids seem to be a useful and cheap tool for investigating energetic processes occurring 
during jet milling. 
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Summary 
The aim of this thesis was to provide more information about the jet milling of proteins, to 
identify important parameters and their effect on resulting particle size, chemical stability and 
bioactivity of the investigated proteins. 
To perform the planned micronization experiments the MC One® of Jetpharma had to be 
modified. A cryogenic cooling system had been established facilitating milling gas 
temperatures of about -60°C in reproducible quality. To exclude possible effects of air 
humidity the whole setup was integrated into a glovebox filled with dry nitrogen. Therefore, it 
was possible to process amounts starting from 200 mg with yields of more than 80 % under 
constant environmental conditions. This way it was possible to attribute all the observed 
effects to controlled parameters (chapter 3). 
The micronization of three different model proteins proved the size reduction potential of jet 
milling. It was possible to achieve narrow particle size distributions with d90 values below 
10 µm for each of the three proteins. Chosen pressure and number of milling cycles had a 
significant impact on the milling results. For the first cycle the size distribution of the bulk 
material played an important role. Especially for the coarse BSA powder some larger particles 
were still present after the first milling cycle. A grinding limit existed for all model proteins at 
about 3-4 µm (d90), implicating that additional milling cycles would have no further effect on 
the particle size. The effect of the third investigated parameter, the milling gas temperature, 
was different for the proteins. No effect was detected for insulin; for lysozyme the particle 
size increased slightly under cryogenic conditions, while a clear decrease was detected for 
BSA. By applying statistical design it was possible to fit mathematical models to all the three 
micronization processes, describing the qualitative and quantitative impact of the parameters 
on the resulting particle size. So the prediction of milling results of not tested parameter 
combinations within the investigated range was enabled (chapter 4). 
It was the second focus of the thesis was to investigate the effect of the jet milling process on 
the chemical stability and the bioactivity of proteins. For insulin no chemical changes were 
observed. The analysis of secondary and tertiary structures revealed slight changes. 
Nevertheless, they seemed to have no effect on the bioactivity investigated, using a 
chondrocyte proliferation assay (chapter 5). 
After micronization chemically no changes were detected for lysozyme compared to the 
unprocessed bulk material. The analysis of the secondary protein structure by CD-
spectroscopy showed no difference either. Regarding the tertiary structure fluorescence 
  References 
125 
analysis revealed significant changes. Especially the relative surface hydrophobicity was 
affected by a 12-fold increase after three milling cycles at 14 bar. Due to these changes the 
bioactivity decreased depending on applied pressure and milling cycles. For three cycles at 
14 bar 87 % of the former activity were measured. In particular repeated milling seemed to 
have a negative effect. The milling gas temperature had no significant effect. An influence of 
increased iron content due to attrition during the milling process was excluded by ICP 
measurements. The attempt of reducing the decrease in bioactivity by using crystalline 
lysozyme brought no advantage for the process (chapter 6). 
For BSA the most prominent effect of the micronization process was the formation of an 
insoluble fraction of the protein. Experiments revealed that all the three investigated milling 
parameters affected this result. With higher pressure and more milling cycles the insoluble 
fraction increased to 14 %. By applying cryogenic conditions the amount had been decreased 
to 6-9 %. This indicates that heat creation on the particle surface may play a role in this 
process, inducing changes within the particles. Different possible reasons for this 
phenomenon were investigated. Covalent protein aggregates due to thiol-disulfide interchange 
could be excluded as a reason as well as oxidation processes of this free thiol group. Increased 
surface hydrophobicity by rearrangement of fatty acids present at the molecule surface could 
be neglected by micronizing fatty acid free BSA. However, changes in relative surface 
hydrophobicity were detected by fluorescence analysis. The micronization process resulted in 
a significant decrease of this value while the intrinsic fluorescence was not affected. A 
correlation to the insoluble BSA fraction was not possible. Attempts to analyse the insoluble 
fraction itself brought no results. Nevertheless, beside the cryomilling approach of reducing 
this fraction, the co-lyophilization of BSA with PEG showed good results. With increasing 
amounts of PEG in the mixture the insoluble fraction decreased. At a BSA PEG ratio of 2:1 
no insoluble BSA could be detected anymore. This effect was referred to the separation of the 
BSA molecules by PEG, preventing intermolecular reactions, and of the hydrophilic 
properties of PEG (chapter 7). 
Processing of glycerol tripalmitate revealed that it is possible to micronize even such a soft 
material by jet milling. It resulted in d90 values below 20 µm. During storage an increase in 
particle size had been observed due to changes in surface structure of the micronized particles. 
DSC analysis revealed that the micronization process induces an activation at the surface. 
During storage these activated areas recrystallized. It was possible to correlate this effect to 
the number of milling cycles and the milling gas temperature. With more milling cycles the 
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effect was more prominent, which was significantly reduced by applying cryogenic conditions 
(chapter 8).  
 
Conclusion 
In conclusion the micronization process of proteins by jet milling was clarified in more detail. 
Particle size reduction was possible for all the tested substances, but different effects on 
chemical stability and bioactivity were revealed, strongly depending on the investigated 
substance. Especially repeated stressing of the materials seemed to have a negative effect and 
should be avoided for sensitive substances. Some effects like the formation of insoluble 
fractions for BSA or structural changes in glycerol tripalmitate were induced by heat 
formation at the breakage surface. In these cases cryomilling had a protective effect and it 
may be worth the additional costs. Therefore, for each new substance the milling conditions 
should be tested carefully. Application of design of experiments for these investigations 
proved to be a useful and cost saving tool. 
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Abbreviations 
 
 
ANOVA  analysis of variances 
ANS   8-anilino-1-naphtalenesolfonic acid 
BSA   bovine serum albumin 
CD   circular dichroism 
CCF   face centered central composite design 
Detapac  dieethylenetriamine-pentacetic acid 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO  dimethylsulfoxide 
DoE   Design of Experiments 
DSC   differential scanning calorimetry 
DTNB   5,5´-dithiobis(2-nitrobenzoic acid), Ellman´s reagent 
FBS   fetal bovine serum 
FDA   Food and Drug Administration 
GSH   l-glutathione 
hGH   human growth hormone 
ICH International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use 
ICP-OES  inductively coupled plasma – optical emission spectroscopy 
IGF   insulin-like growth factor 
MALDI-ToF matrix-assisted laser desorption/ionization time of flight mass 
spectrometer 
PEG   polyethylene glycol 
PLGA   poly(lactic-co-glycolic acid) 
PSH   protein surface hydrophobicity 
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PTFE   polytetrafluoroethylene 
RH   relative humidity 
RSH   relative surface hydrophobicity 
SCF   super critical fluid 
SDS   sodium dodecyl sulfate 
SEM   scanning electron microscope 
SFD   spray freeze drying 
SFL   spray freezing into liquid 
SH   sulfhydryl 
TFA   trifluoroacetic acid 
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Additional data for the experimental design 
In this section the statistical data for all responses of the experimental design are given. The 
summary list for the statistical evaluation of the models, the ANOVA lists for the evaluation 
of the responses as well as the coefficient lists for the determination of the significance of the 
investigated factors and interactions thereof. All statistical data was evaluated at a confidence 
level of 0.95. 
 
Particle size (d90-value) for insulin (chapter 4) 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 0.70807 0.08918 4.06164e-006 0.1943 
Pre -0.08506 0.01011 2.23664e-006 0.02203 
Cyc -0.05011 0.01412 0.004 0.03076 
Temp 0.00853 0.0138 0.54814 0.03006 
Pre*Pre 0.0765 0.01687 0.00068 0.03675 
Cyc*Cyc 0.00652 0.01491 0.66972 0.03248 
Temp*Temp -0.15922 0.11353 0.18613 0.24736 
Pre*Cyc -0.01062 0.01239 0.40824 0.027 
Pre*Temp -0.00054 0.01756 0.97596 0.03826 
Cyc*Temp -0.02281 0.01677 0.1986 0.03653 
Table 1 coefficient list (significant factors printed in bold) 
 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 0.58792 0.01058 1.36293e-021 0.02222 
Pre -0.07906 0.00965 1.75528e-007 0.02028 
Cyc -0.06434 0.00965 2.9787e-006 0.02028 
Pre*Pre 0.08917 0.01432 7.10362e-006 0.03009 
Table 2 coefficient list after exclusion of insignificant factors 
 
d90 DF SS MS (variance) F p SD 
Total 22 9.10276 0.41376       
Constant 1 8.91457 8.91457       
              
Total Corrected 21 0.18819 0.00896     0.09467 
Regression 3 0.16806 0.05602 50.0803 0.000 0.23668 
Residual 18 0.02013 0.00112     0.03345 
              
Lack of Fit 14 0.01422 0.00102 0.68664 0.732 0.03187 
(Model Error)             
Pure Error 4 0.00592 0.00148     0.03846 
(Replicate Error)             
Table 3 Anova list 
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  R2 R2 Adj. Q2 SD RSD N Model Validity Reproducibility 
d90 0.89301 0.87518 0.83723 0.09467 0.03345 22 0.92201 0.83495 
N = 22  DF = 18 Cond. no. =2.7386 Y-miss =0 
Table 4 Summary list for statistical evaluation of experimental design for d90-value of insulin 
 
 
Particle size (d90-value) for lysozyme (chapter 4) 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 0.79691 0.07037 9.20315e-008 0.15333 
Pre -0.06524 0.00669 4.68248e-007 0.014573 
Cyc -0.07671 0.00673 8.55599e-008 0.014663 
Temp -0.05635 0.00668 2.18011e-006 0.01456 
Pre*Pre 0.00941 0.00811 0.2683 0.01766 
Cyc*Cyc 0.02083 0.00778 0.02016 0.01695 
Temp*Temp -0.03785 0.07522 0.62398 0.16389 
Pre*Cyc 0.01175 0.00622 0.08329 0.01355 
Pre*Temp -0.00308 0.01341 0.82204 0.02921 
Cyc*Temp 0.00854 0.00697 0.24409 0.01519 
Table 5 coefficient list (significant factors printed in bold) 
 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 0.76807 0.00975 3.09893e-023 0.02057 
Pre -0.06491 0.00675 2.7303e-008 0.01424 
Cyc -0.07925 0.00673 1.33813e-009 0.0142 
Temp -0.05372 0.00675 3.91394e-007 0.01424 
Cyc*Cyc 0.02275 0.00754 0.00780 0.01592 
Table 6 coefficient list after exclusion of insignificant factors 
 
d90 DF SS MS (variance) F p SD 
Total 22 14.0147 0.63703       
Constant 1 13.7225 13.7225       
              
Total Corrected 21 0.2922 0.013914     0.11796 
Regression 4 0.27604 0.06901 72.5879 0.000 0.2627 
Residual 17 0.01616 0.00095     0.03083 
              
Lack of Fit 13 0.01174 0.00090 0.818115 0.651 0.03006 
(Model Error)             
Pure Error 4 0.00442 0.0011     0.03323 
(Replicate Error)             
Table 7 Anova list 
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  R2 R2 Adj. Q2 SD RSD N Model Validity Reproducibility 
d90 0.944689 0.93167 0.90294 0.11796 0.03083 22 0.89271 0.92064 
N = 22  DF = 17 Cond. no. =2.6934 Y-miss =0 
Table 8 Summary list for statistical evaluation of experimental design for d90-value of lysozyme 
 
 
Particle size (d90-value) for BSA (chapter 4) 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 1.12121 0.08118 9.9557e-009 0.17688 
pre -0.10374 0.01024 3.11504e-007 0.02231 
cyc -0.11162 0.01035 1.57715e-007 0.02256 
temp 0.02207 0.01028 0.05293 0.0224 
pre*pre 0.05093 0.01658 0.00969 0.03613 
cyc*cyc 0.0397 0.01577 0.02708 0.03437 
temp*temp -0.27678 0.10727 0.02409 0.23373 
pre*cyc 0.04152 0.01263 0.0065 0.02752 
pre*temp -0.09533 0.02283 0.00129 0.04974 
cyc*temp -0.00388 0.01186 0.74906 0.02584 
Table 9 coefficient list (significant factors printed in bold) 
 
d90 Coeff. SC Std. Err. P Conf. int(±) 
Constant 1.11603 0.07684 2.05311e-009 0.166 
pre -0.10375 0.00988 1.0209e-007 0.02135 
cyc -0.11185 0.00997 4.66039e-008 0.02154 
temp 0.02166 0.00985 0.04652 0.02127 
pre*pre 0.05044 0.01594 0.00745 0.03443 
cyc*cyc 0.03988 0.01521 0.02114 0.03287 
temp*temp -0.26976 0.10144 0.01965 0.21914 
pre*cyc 0.04175 0.01217 0.00448 0.0263 
pre*temp -0.09409 0.02173 0.00082 0.04693 
Table 10 coefficient list after exclusion of insignificant factors 
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d90 DF SS MS (variance) F p SD 
Total 22 20.6863 0.94029       
Constant 1 20.3153 20.3153       
              
Total Corrected 21 0.37095 0.01766     0.13291 
Regression 8 0.35581 0.04448 38.1953 0.000 0.2109 
Residual 13 0.01514 0.001164     0.03412 
              
Lack of Fit 9 0.00508 0.00056 0.22447 0.971 0.02376 
(Model Error)             
Pure Error 4 0.01006 0.00251     0.05015 
(Replicate Error)             
Table 11 Anova list 
 
  R2 R2 Adj. Q2 SD RSD N Model Validity Reproducibility 
d90 0.95919 0.93408 0.90856 0.13291 0.03412 22 0.99255 0.85765 
N = 22  DF = 13 Cond. no. =26.8749 Y-miss =0 
Table 12 Summary list for statistical evaluation of experimental design for d90-value of BSA 
 
 
Bioactivity of lysozyme (chapter 6) 
Activity Coeff. SC Std. Err. P Conf. int(±) 
Constant 89.1616 3.12135 2.10399e-012 6.8008 
Pre -1.29778 0.29666 0.0009 0.64637 
Cyc -3.00796 0.29849 3.29486e-007 0.65034 
Temp 0.74775 0.29633 0.02674 0.64565 
Pre*Pre 0.20269 0.35951 0.58328 0.78331 
Cyc*Cyc 0.28067 0.34513 0.43193 0.75197 
Temp*Temp 2.53408 3.33625 0.46218 7.26903 
Pre*Cyc -0.11668 0.27579 0.67973 0.6009 
Pre*Temp -0.68397 0.59462 0.27245 1.29557 
Cyc*Temp 0.53595 0.30919 0.10862 0.67366 
Table 13 coefficient list (significant factors printed in bold) 
 
Activity Coeff. SC Std. Err. P Conf. int(±) 
Constant 92,0864 0,37561 3,58467e-033 0,78914 
Pre -1,27052 0,38561 0,00403 0,81013 
Cyc -2,99871 0,38448 3,51184e-007 0,80776 
Temp 0,68222 0,38563 0,09382 0,81019 
Table 14 coefficient list after exclusion of insignificant factors (significant factors printed in bold) 
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Activity Coeff. SC Std. Err. P Conf. int(±) 
Constant 92.0864 0.39584 2.73454e-034 0.82852 
Pre -1.32917 0.40516 0.00393 0.84802 
Cyc -3.00482 0.40516 5.06633e-007 0.84802 
Table 15 coefficient list after exclusion of insignificant factors 
 
Activity DF SS MS (variance) F p SD 
Total 22 186850 8493.18       
Constant 1 186558 186558       
              
Total Corrected 21 292.203 13.9144     3.73021 
Regression 2 226.706 113.353 32.8821 0.000 10.6467 
Residual 19 65.4976 3.44724     1.85668 
              
Lack of Fit 15 60.1043 4.00695 2.97178 0.151 2.00174 
(Model Error)             
Pure Error 4 5.39334 1.34833     1.16118 
(Replicate Error)             
Table 16 Anova list 
 
  R2 R2 Adj. Q2 SDY RSD N Model 
Validity 
Reproducibility 
Activity 0.775851 0.752254 0.706127 3.73022 1.85668 22 0.526519 0.903098 
N = 22  DF = 19 Cond. no. =1.0235 Y-miss =0 
Table 17 Summary list for statistical evaluation of experimental design for bioactivity of lysozyme 
 
Insoluble BSA fraction (chapter 7) 
insoluble fraction Coeff. SC Std. Err. P Conf. int(±) 
Constant 8.6635 1.12161 5.37506e-006 2.44377 
pre 2.12488 0.14149 3.83282e-009 0.30827 
cyc 1.27967 0.14302 1.17447e-006 0.31162 
temp 1.43366 0.14203 3.23714e-007 0.30946 
pre*pre 1.84723 0.22908 3.46603e-006 0.49912 
cyc*cyc -0.23992 0.21793 0.29253 0.47482 
temp*temp -1.94042 1.48207 0.21496 3.22914 
pre*cyc -0.42425 0.17452 0.03168 0.38025 
pre*temp 1.23938 0.31541 0.002 0.68721 
cyc*temp 0.14553 0.16383 0.39183 0.35694 
Table 18 coefficient list (significant factors printed in bold) 
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insoluble fraction Coeff. SC Std. Err. P Conf. int(±) 
Constant 7.12295 0.16027 2.43886e-017 0.34161 
pre 2.12998 0.14661 3.04458e-010 0.31248 
cyc 1.25493 0.14618 3.57311e-007 0.31157 
temp 1.33229 0.12294 1.71859e-008 0.26204 
pre*pre 1.70266 0.21743 1.1192e-006 0.46344 
pre*cyc -0.46773 0.17903 0.0196 0.38158 
pre*temp 1.59827 0.16392 6.96364e-008 0.34939 
Table 19 coefficient list after exclusion of insignificant factors 
 
insoluble fraction DF SS MS (variance) F p SD 
Total 22 1550 70.4545       
Constant 1 1411.2 1411.2       
              
Total Corrected 21 138.798 6.60942     2.57088 
Regression 6 134.952 22.492 87.7324 0.000 4.74258 
Residual 15 3.84557 0.256371     0.50633 
              
Lack of Fit 11 3.01519 0.27411 1.3204 0.426 0.52355 
(Model Error)             
Pure Error 4 0.83038 0.2076     0.45563 
(Replicate Error)             
Table 20 Anova list 
 
  R2 R2 
Adj. 
Q2 SDY RSD N Model 
Validity 
Reproducibility 
insoluble 
fraction 
0.97229 0.96121 0.92265 2.57088 0.50633 22 0.78636 0.96859 
N = 22  DF = 15 Cond. no. =2.7534 Y-miss =0 
Table 21 Summary list for statistical evaluation of experimental design for insoluble fraction of BSA 
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“He, who breaks a thing to find out what it is, has left the path of wisdom.” 
Lord of the Rings by J.R.R. Tolkien 
